Thursday, October 2, 2025

Antimicrobial Stewardship in Practice: The Hospitalist's Role

A Practical Guide for the Frontline Clinician

Dr Neeraj Manikath , claude.ai

Abstract

Antimicrobial stewardship (AMS) is no longer the exclusive domain of infectious disease specialists or pharmacy teams—it is a critical competency for every hospitalist managing acutely ill patients. This review provides a practical, evidence-based approach to implementing AMS principles at the bedside, with particular emphasis on metrics that matter (Days of Therapy), strategic de-escalation, optimizing routes of administration, appropriate treatment durations, and the crucial art of antimicrobial communication. We present actionable "pearls" derived from contemporary literature and real-world implementation science to transform stewardship from a compliance exercise into excellent clinical practice.

Keywords: Antimicrobial stewardship, hospitalist, de-escalation, antibiotic duration, IV to PO switch, antimicrobial resistance

Introduction

The World Health Organization has declared antimicrobial resistance (AMR) one of the top ten global public health threats.>1 In the United States alone, antibiotic-resistant infections cause over 2.8 million infections and 35,000 deaths annually.Hospitalists, as the physicians managing the majority of acutely ill medical patients, are uniquely positioned to impact antimicrobial use through thoughtful prescribing, timely reassessment, and effective stewardship interventions.>3

The traditional paradigm of "start broad, consult ID if they don't improve" is no longer acceptable. Modern antimicrobial stewardship requires active engagement from frontline clinicians at multiple decision points: initial empiric selection, early de-escalation based on microbiology and clinical response, route optimization, duration determination, and the often-difficult conversation about stopping therapy.4

This review focuses on five high-impact stewardship practices that every hospitalist can implement immediately, supported by contemporary evidence and designed for practical application in the time-pressured hospital environment.

1. The "Days of Therapy" and Why It Matters

Beyond Crude Consumption: Understanding DOT

Antimicrobial stewardship programs traditionally tracked antibiotic use through Defined Daily Doses (DDD), a WHO metric designed for international comparisons. However, Days of Therapy (DOT) has emerged as the superior metric for hospital stewardship because it more accurately reflects actual prescribing behavior and accounts for weight-based and renally-adjusted dosing.

DOT Definition: One DOT = one antimicrobial agent administered to one patient on a given day, regardless of the number of doses or dosage strength.

Why DOT Matters Clinically:

It reveals prescribing patterns: High DOT rates may indicate delayed de-escalation, prolonged empiric therapy, or inappropriate prophylaxis
It's actionable: Unlike DDDs, DOT directly correlates with stewardship interventions (stopping redundant coverage, switching IV to PO, shortening durations)
It predicts outcomes: Excessive antimicrobial exposure (high DOT) correlates with Clostridioides difficile infection, multidrug-resistant organisms, and adverse drug events7,8

Pearl: The "Spectrum Score" Approach

When reviewing patients on rounds, mentally assign a "spectrum score" to each antimicrobial regimen:

Score 1: Narrow-spectrum, pathogen-directed (e.g., ceftriaxone for S. pneumoniae bacteremia)
Score 3: Moderate-spectrum empiric (e.g., ceftriaxone + azithromycin for CAP)
Score 5: Broad-spectrum anti-pseudomonal (e.g., piperacillin-tazobactam + vancomycin)
Score 7+: "Desperation regimen" (e.g., meropenem + linezolid + micafungin)

The goal: Decrease the spectrum score daily as clinical and microbiological data accumulate. If the score isn't decreasing by day 3-4, ask why.

Oyster: The DOT Paradox

Paradoxically, some effective stewardship interventions may increase DOT while improving outcomes. For example, replacing fluoroquinolone monotherapy with beta-lactam + macrolide for severe community-acquired pneumonia increases DOT (from 1 to 2 agents) but improves mortality in critically ill patients. Clinical wisdom: DOT is a process measure, not an outcome. Always prioritize patient outcomes over metrics.

2. The Magic of De-escalation: From Broad-Spectrum to Targeted Therapy

The Evidence Base

De-escalation—narrowing or stopping antimicrobial therapy based on clinical improvement and microbiological data—is perhaps the most powerful stewardship intervention.11A meta-analysis of 12 studies involving over 6,000 patients demonstrated that de-escalation in sepsis and severe infections is safe (no increase in mortality; pooled OR 0.51, 95% CI 0.37-0.69) and reduces antimicrobial pressure.12

The De-escalation Framework: "Culture, Clinical, Coverage"

Day 1-2 (Empiric Phase): Broad-spectrum appropriate for severity of illness and local resistance patterns

Day 3-5 (De-escalation Window): Reassess using three C's:

Culture Data:
- If cultures identify a pathogen: narrow to the most specific agent with the narrowest spectrum
- If cultures are negative after 48-72 hours in a clinically improving patient: consider stopping antibiotics (especially for suspected but unconfirmed infections)
Clinical Response:
- Temperature trending down
- Hemodynamic stability
- Improving organ function (e.g., decreasing vasopressor requirements, rising PaO₂/FiO₂)
- Decreasing inflammatory markers (though biomarker-guided therapy remains controversial)13
Coverage Assessment:
- Is continued Gram-negative coverage necessary? (Can piperacillin-tazobactam become ceftriaxone?)
- Is MRSA coverage still indicated? (Discontinue vancomycin if blood cultures negative at 48 hours unless clinical MRSA syndrome confirmed)14
- Is anaerobic coverage needed? (Most aspiration pneumonia does NOT require anaerobic coverage)15

Pearl: The "48-Hour Hard Stop"

Implement this rule: All empiric broad-spectrum regimens (especially vancomycin + piperacillin-tazobactam or meropenem) require active reassessment and documentation of continued need at 48 hours. This can be enforced through:

Electronic health record (EHR) alerts
Pharmacist-driven protocols with automatic de-escalation if criteria met
Stewardship "timeouts" during interdisciplinary rounds16

In one quaternary center study, automated 48-hour "hard stops" on empiric vancomycin reduced unnecessary MRSA coverage by 35% without adverse outcomes.17

Oyster: The "Double Coverage" Fallacy

Many clinicians maintain combination therapy (e.g., two antipseudomonal agents) based on outdated beliefs about synergy and resistance prevention. Current evidence: For most infections—including Pseudomonas bacteremia—monotherapy with an active agent is non-inferior to combination therapy once susceptibilities are known.18,19

Exception: Reserve combination therapy for:

Extensively drug-resistant Gram-negatives where monotherapy options are marginal
Initial empiric therapy in critically ill patients with high risk of MDR pathogens (then de-escalate to monotherapy)
Selected cases of Pseudomonas bacteremia in neutropenic patients (though evidence is mixed)20

Hack: The "Culture Conversion" Conversation

When cultures identify Streptococcus pneumoniae, Escherichia coli, or other common pathogens susceptible to narrow-spectrum agents, frame de-escalation positively to the team:

"Great news—cultures grew S. pneumoniae sensitive to penicillin. We can convert from vancomycin + ceftriaxone to penicillin G, which is more targeted, cheaper, and reduces selection pressure for resistant organisms."

This frames stewardship as optimization rather than restriction.

3. IV to PO Switch: Criteria and Opportunities

The Clinical and Economic Imperative

Intravenous antimicrobials are associated with increased costs, longer hospital stays, phlebitis, line-related bloodstream infections, and patient immobility.21 Conversely, oral antibiotics with high bioavailability achieve therapeutic serum levels comparable to IV formulations for many infections.

The 3 A's: A Simple Decision Framework

An IV-to-PO switch should be considered when patients meet the 3 A's:22

Afebrile: Temperature <38°C for at least 24 hours (some extend this to 8-24 hours depending on infection severity)
Able: Functioning GI tract (not actively vomiting, no ileus, no malabsorption syndrome)
Awake: Alert and able to take oral medications safely

High-Bioavailability Oral Agents: The Stewardship "Go-To" List

IV Antibiotic	PO Alternative	Bioavailability	Clinical Context
Vancomycin	Linezolid	~100%	MRSA infections (not endocarditis or meningitis)
Levofloxacin IV	Levofloxacin PO	~99%	Pneumonia, UTI (identical dosing)
Fluconazole IV	Fluconazole PO	>90%	Candidemia after clinical stability
Metronidazole IV	Metronidazole PO	>80%	Most anaerobic infections
Moxifloxacin IV	Moxifloxacin PO	~90%	CAP, intra-abdominal infections
Trimethoprim-sulfamethoxazole IV	TMP-SMX PO	~85%	Diverse infections (UTI, MRSA, Stenotrophomonas)

Pearl: "Same Drug, Different Route" Transitions

For antibiotics with near-perfect bioavailability (fluoroquinolones, linezolid, metronidazole, fluconazole), the IV-to-PO switch is essentially the same drug by a different route—not a therapeutic change. This can be implemented via pharmacist-driven protocols without physician approval in many institutions, accelerating appropriate transitions.23

Oyster: The Beta-Lactam Challenge

Beta-lactams (penicillins, cephalosporins) have variable oral bioavailability, and IV-to-PO transitions are not equivalent. For example:

Ceftriaxone IV cannot be "converted" to oral cephalexin for bacteremia—these are different drugs with different spectra
For serious infections (bacteremia, osteomyelitis), oral beta-lactams may be inadequate; consider prolonged IV therapy or high-bioavailability alternatives (e.g., fluoroquinolones if susceptible)

Exception: Oral amoxicillin-clavulanate and oral cefdinir/cefpodoxime can be appropriate step-downs for community-acquired infections like CAP after initial IV stabilization 24

Hack: The "Early Switch" Protocol

Implementation strategy: Create an institutional protocol where pharmacy or nursing automatically notifies the team when patients meet the 3 A's criteria, with opt-out (rather than opt-in) consent for high-bioavailability agents. One study showed this increased appropriate IV-to-PO switches from 42% to 78% and reduced length of stay by 0.6 days.25

4. The Duration Debate: Short-Course Therapy for Common Infections

Paradigm Shift: Shorter is Often Better

Historical antibiotic durations (e.g., 10-14 days for pneumonia, 7-14 days for UTI) were based on tradition and expert opinion rather than rigorous evidence.26 Over the past decade, multiple randomized controlled trials have demonstrated that shorter courses are non-inferior for most common infections, with reduced adverse events and lower risk of resistance.27

Evidence-Based Durations for Hospitalist-Managed Infections

Community-Acquired Pneumonia (CAP)

Traditional duration: 7-10 days
Evidence-based duration: 5 days for most patients

Landmark trial: A meta-analysis of 21 RCTs (N=5,426) found short-course therapy (≤5 days) non-inferior to longer courses for CAP, with similar clinical cure rates and mortality.28
IDSA/ATS guidelines (2019): Recommend a minimum of 5 days for CAP in patients who are clinically stable (afebrile ≥48 hours, improving symptoms, no more than 1 CAP-associated sign of clinical instability).29

Pearl: Use the Halm Criteria to identify patients stable for discharge/completion of therapy:30

Temperature ≤37.8°C
Heart rate ≤100 bpm
Respiratory rate ≤24/min
Systolic BP ≥90 mmHg
Oxygen saturation ≥90% or PaO₂ ≥60 mmHg on room air
Ability to take oral medications
Normal mental status

Oyster: Patients with bacteremic S. aureus pneumonia, necrotizing pneumonia, or empyema still require prolonged therapy (2-4 weeks); short-course principles do NOT apply to these complicated scenarios.

Healthcare-Associated Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)

Traditional duration: 14-21 days
Evidence-based duration: 7-8 days for most patients

The PneumA trial randomized 310 VAP patients to 8 vs. 15 days of antibiotics—no difference in mortality, recurrence, or length of stay.31
Exception: Non-fermenting Gram-negatives (Pseudomonas, Acinetobacter) may have higher recurrence with 7-8 day courses; consider extending to 10-14 days, though evidence is mixed.32

Uncomplicated Pyelonephritis

Traditional duration: 10-14 days
Evidence-based duration: 5-7 days with fluoroquinolones or beta-lactams

A Cochrane review of 15 trials found short-course therapy (5-7 days) non-inferior to longer courses for uncomplicated pyelonephritis.33
Fluoroquinolone monotherapy × 5-7 days or ceftriaxone + oral step-down × 7 days total is appropriate for most cases.34

Bloodstream Infections (Uncomplicated)

Traditional duration: 14 days
Evidence-based duration: 7 days for Gram-negative bacteremia without complications

The BALANCE trial (N=3,608) demonstrated that 7 days of antibiotics was non-inferior to 14 days for patients with Gram-negative bacteremia and negative follow-up blood cultures.35
Key criteria for short course: Source controlled, no metastatic infection (e.g., endocarditis, osteomyelitis), clearance of bacteremia documented by repeat negative cultures

Oyster: Staphylococcus aureus bacteremia (SAB) is the major exception—minimum 14 days required (4-6 weeks if endocarditis or complicated infection). Never shorten SAB treatment without ID consultation.36

Intra-Abdominal Infections (IAI)

Traditional duration: Continue until resolution of leukocytosis and fever
Evidence-based duration: 4 days after source control

The STOP-IT trial randomized 518 IAI patients to antibiotics until resolution of clinical signs vs. fixed 4-day course—no difference in outcomes, but significantly shorter antibiotic exposure in the fixed-duration group.37
Guideline recommendation: Limit antibiotics to 4-5 days after adequate source control for community-acquired IAI.38

Pearl: The "Pre-Discharge Duration Discussion"

On day 3-4 of therapy, proactively document the planned total duration and end date in your progress note:

"Plan to complete 5-day course for CAP (last day: [DATE]). Will reassess if clinical deterioration."

This prevents the common problem of antibiotics being continued "because nobody said to stop."

Hack: The "Auto-Stop" Order

Program your EHR to default antibiotic orders to evidence-based durations with automatic stop dates:

CAP → 5 days
HAP/VAP → 7 days
Uncomplicated GNR bacteremia → 7 days
IAI (source controlled) → 4 days

Clinicians can override with documented justification, but the default guides appropriate prescribing.39

5. How to Talk to Colleagues About Stopping or Narrowing Antibiotics

The "Stewardship Conversation" Challenge

Perhaps the most underappreciated aspect of antimicrobial stewardship is the interpersonal skill required to advocate for appropriate prescribing without alienating colleagues, undermining confidence, or creating patient safety concerns.40 Hospitalists must navigate conversations with:

Admitting teams reluctant to narrow "because the patient is still sick"
Surgeons demanding continued broad-spectrum coverage "just in case"
Consultants who reflexively recommend prolonged courses
Families fearful that stopping antibiotics means "giving up"

Framework for Effective Stewardship Communication

1. Open with Shared Goals

Begin by aligning on the common objective—patient safety and optimal outcomes.

Instead of: "You're using too many antibiotics."
Try: "I want to make sure we're giving [patient] the most effective, targeted therapy while minimizing risks like C. diff and drug toxicity."

2. Use Data, Not Judgment

Present objective clinical and microbiological data to support your recommendation.

Example:
"Blood cultures have been negative for 48 hours, and she's been afebrile for 36 hours. Based on the 2019 IDSA guidelines, we can safely discontinue vancomycin at this point."

3. Employ the "What Would Make You Comfortable?" Technique

If a colleague is resistant, explore their concerns directly.

Example:
"I hear your concern about stopping antibiotics while she still has a leukocytosis. What specific clinical milestone would make you comfortable with de-escalation? Follow-up cultures? One more afebrile day?"

This shifts the conversation from confrontation to collaboration.41

4. Frame Stewardship as "Optimizing" Not "Restricting"

Avoid language that implies rationing or cost-cutting.

Instead of: "We need to cut back on broad-spectrum antibiotics."
Try: "Now that we have culture data, we can optimize to the most targeted agent—linezolid is actually more effective for MRSA soft tissue infections than vancomycin with better tissue penetration."

5. The "Antibiotic Timeout"

Implement a structured interdisciplinary discussion (akin to a surgical timeout) at 48-72 hours of therapy:42

Review indication: Is there a documented infection or is this empiric for possible infection?
Review cultures: Do results allow narrowing?
Review response: Is the patient improving? Deteriorating?
Review duration: What is the planned end date?

This provides a non-threatening forum for stewardship conversations.

6. Leverage Pharmacy and ID Consultation

If direct hospitalist-to-hospitalist or hospitalist-to-consultant conversations are unproductive, involve antimicrobial stewardship pharmacists or ID physicians as neutral third parties. They can provide recommendations without the interpersonal dynamics of frontline team-to-team conflict.43

Pearl: The "Culture Negative, Clinically Well" Algorithm

For patients with negative cultures after 48-72 hours who are clinically improving:

Present the data:
"All cultures are negative, inflammatory markers trending down, patient afebrile and improving. In this scenario, continuing empiric broad-spectrum antibiotics increases risk of C. diff and resistance without added benefit."

Offer a safety net:
"We can stop now and monitor closely. If there's any clinical deterioration, we can always restart."

This acknowledges uncertainty while advocating for evidence-based practice.44

Oyster: The "Never Say Never" Principle

Avoid absolutes like "This patient definitely doesn't need antibiotics." Medicine is probabilistic, and stewardship recommendations should reflect this:

Instead of: "This is not an infection; stop the antibiotics."
Try: "Based on available data, infection is less likely. We could consider stopping antibiotics while monitoring closely for clinical changes."

This maintains credibility if the clinical situation evolves.45

Hack: The "Stewardship Template" Note

Create a standardized note template for stewardship recommendations:

ANTIMICROBIAL STEWARDSHIP RECOMMENDATION

Current regimen: [List antibiotics, day of therapy]

Indication: [e.g., CAP, HAP, bacteremia]

Cultures: [Results, including negatives]

Clinical status: [Vital signs, inflammatory markers, trends]

Recommendation:
☐ De-escalate to [narrow-spectrum agent]
☐ Convert IV → PO
☐ Shorten duration to [X days total]
☐ Discontinue [specific agent]

Evidence base: [Cite guideline or trial]

Risk/benefit: [Address specific patient factors]

Happy to discuss further—contact ASP at [extension]

This formalizes stewardship as a clinical service (like any consultation) and provides documentation for quality metrics.46

Conclusion: The Hospitalist as Steward

Antimicrobial stewardship is not an optional quality improvement project—it is a core clinical competency for hospitalists in the 21st century. Every antibiotic prescription is an opportunity to practice stewardship: selecting the narrowest-spectrum agent appropriate for the infection, planning de-escalation from the moment of empiric initiation, optimizing the route of administration, defining a rational duration, and advocating effectively for appropriate use.

The interventions outlined in this review—tracking DOT, implementing 48-hour hard stops, applying the 3 A's for IV-to-PO switches, adopting evidence-based short-course durations, and mastering stewardship communication—are immediately actionable and supported by robust evidence.

The bottom line: Excellent antimicrobial stewardship is simply excellent clinical medicine. When we prescribe antibiotics thoughtfully, reassess frequently, and stop promptly when appropriate, we simultaneously optimize individual patient outcomes and preserve the effectiveness of these life-saving drugs for future generations.

As hospitalists, we cannot afford to delegate this responsibility. The stewardship is the practice.

Key Pearls and Oysters: Summary

Pearls

The Spectrum Score: Assign a daily "spectrum score" to antimicrobial regimens and aim to decrease it as clinical data accumulate
The 48-Hour Hard Stop: All empiric broad-spectrum regimens require active reassessment at 48 hours
The 3 A's: Afebrile, Able, Awake—simple criteria for IV-to-PO conversion
The Halm Criteria: Use these validated stability criteria to determine CAP treatment completion
Pre-Discharge Duration Discussion: Document the planned end date of antibiotics on day 3-4 to prevent inadvertent continuation
The "Culture Negative, Clinically Well" Algorithm: Stopping antibiotics in improving patients with negative cultures is safe and evidence-based

Oysters

The DOT Paradox: Some stewardship interventions increase DOT while improving outcomes—always prioritize patient outcomes over metrics
The "Double Coverage" Fallacy: Combination therapy for Gram-negatives is rarely necessary once susceptibilities are known
The Beta-Lactam Challenge: IV-to-PO beta-lactam switches are not equivalent; oral alternatives often have different spectra and bioavailability
The SAB Exception: Never shorten S. aureus bacteremia treatment without ID consultation—minimum 14 days required
The "Never Say Never" Principle: Avoid absolutes in stewardship recommendations; medicine is probabilistic

Hacks

The "Culture Conversion" Conversation: Frame de-escalation as optimization rather than restriction
The "Early Switch" Protocol: Implement opt-out IV-to-PO protocols for high-bioavailability agents
The "Auto-Stop" Order: Default EHR antibiotic orders to evidence-based durations
The "Antibiotic Timeout": Structured 48-72 hour team discussions using a standardized framework
The "Stewardship Template" Note: Formalize recommendations with evidence-based documentation

References

World Health Organization. Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014.
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
Srinivasan A, et al. Antimicrobial stewardship: a hospitalist's role in the era of antibiotic resistance. J Hosp Med. 2018;13(11):792-795.
Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51-e77.
World Health Organization Collaborating Centre for Drug Statistics Methodology. Definition and general considerations. Available at: https://www.whocc.no/ddd/definition_and_general_considera/. Accessed January 2025.
Ibrahim OM, Polk RE. Antimicrobial use metrics and benchmarking to improve stewardship outcomes: methodology, opportunities, and challenges. Infect Dis Clin North Am. 2014;28(2):195-214.
Baggs J, Fridkin SK, Pollack LA, Srinivasan A, Jernigan JA. Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012. JAMA Intern Med. 2016;176(11):1639-1648.
Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(4):881-891.
Stenehjem E, Hersh AL, Buckel WR, et al. Impact of implementing antibiotic stewardship programs in 15 small hospitals: a cluster-randomized intervention. Clin Infect Dis. 2018;67(4):525-532.
Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med. 2001;161(15):1837-1842.
Tabah A, Cotta MO, Garnacho-Montero J, et al. A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit. Clin Infect Dis. 2016;62(8):1009-1017.
Silva BNG, Andriolo RB, Atallah ÁN, Salomão R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev. 2013;(3):CD007934.
Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107.
Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-e55.
Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001;344(9):665-671.
Filice GA, Drekonja DM, Thurn JR, et al. Use of a computer decision support system and antimicrobial therapy appropriateness. Infect Control Hosp Epidemiol. 2013;34(6):558-565.
Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists. Am J Health Syst Pharm. 2020;77(11):835-864.
Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2006;(1):CD003344.
Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents. 2013;41(4):301-310.
Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450-470.
Cyriac JM, James E. Switch over from intravenous to oral therapy: A concise overview. J Pharmacol Pharmacother. 2014;5(2):83-87.
Mertz D, Koller M, Haller P, et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. J Antimicrob Chemother. 2009;64(1):188-199.
Shrayteh ZM, Rahal MK, Malaeb DN. Practice of switch from intravenous to oral antibiotics. Springerplus. 2014;3:717.
Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012;380(9840):484-490.
Kuti EL, Kuti JL, Nightingale CH, Nicolau DP. Pharmacoeconomic impact and clinical outcomes of a pharmacist-managed i.v. to p.o. antimicrobial conversion program. Expert Rev Pharmacoecon Outcomes Res. 2006;6(6):627-632.
Spellberg B. The new antibiotic mantra—"Shorter is better." JAMA Intern Med. 2016;176(9):1254-1255.
Vaughn VM, Flanders SA, Sneller A, et al. Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: a multihospital cohort study. Ann Intern Med. 2019;171(3):153-163.
Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs. 2008;68(13):1841-1854.
Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice gui

deline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67.

Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279(18):1452-1457.
Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588-2598.
Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111.
Pohl A. Modes of administration of antibiotics for symptomatic severe urinary tract infections. Cochrane Database Syst Rev. 2007;(4):CD003237.
Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120.
Yahav D, Franceschini E, Koppel F, et al. Seven versus 14 days of antibiotic therapy for uncomplicated Gram-negative bacteremia: a noninferiority randomized controlled trial. Clin Infect Dis. 2019;69(7):1091-1098.
Holland TL, Arnold C, Fowler VG Jr. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA. 2014;312(13):1330-1341.
Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996-2005.
Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(1):133-164.
Heil EL, Kuti JL, Bearden DT, Dupont RP. The essential role of pharmacists in antimicrobial stewardship. Infect Control Hosp Epidemiol. 2016;37(7):753-754.
Linkin DR, Paris S, Fishman NO, Metlay JP. Inaccurate communications in telephone calls to an antimicrobial stewardship program. Infect Control Hosp Epidemiol. 2006;27(7):688-694.
Sikkens JJ, van Agtmael MA, Peters EJG, et al. Behavioral approach to appropriate antimicrobial prescribing in hospitals: the Dutch Unique Method for Antimicrobial Stewardship (DUMAS) participatory intervention study. JAMA Intern Med. 2017;177(8):1130-1138.
Pulcini C, Williams F, Molinari N, Davey P, Nathwani D. Junior doctors' knowledge and perceptions of antibiotic resistance and prescribing: a survey in France and Scotland. Clin Microbiol Infect. 2011;17(1):80-87.
Dodds Ashley ES, Kaye KS, DePestel DD, Hermsen ED. Antimicrobial stewardship: philosophy versus practice. Clin Infect Dis. 2014;59(Suppl 3):S112-S121.
Nussenblatt V, Avdic E, Berenholtz S, et al. Ventilator-associated pneumonia: overdiagnosis and treatment are common in medical and surgical intensive care units. Infect Control Hosp Epidemiol. 2014;35(3):278-284.
Livorsi DJ, Nair R, Lund BC, Alexander B, Beck BF, Scheetz MH, Perencevich EN. Antibiotic stewardship implementation: challenges and lessons learned from a multihospital collaborative study. Infect Control Hosp Epidemiol. 2017;38(9):1116-1119.
Pollack LA, Srinivasan A. Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention. Clin Infect Dis. 2014;59(Suppl 3):S97-S100.
Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med. 2017;177(9):1308-1315.
Doernberg SB, Abbo LM, Burdette SD, et al. Essential resources and strategies for antibiotic stewardship programs in the acute care setting. Clin Infect Dis. 2018;67(8):1168-1174.
Vaughn VM, Gandhi TN, Conlon A, et al. Antibiotic overuse after discharge from US hospitals, 2016-2019. JAMA. 2021;326(18):1873-1875.
Lee TC, Frenette C, Jayaraman D, Green L, Pilote L. Antibiotic self-stewardship: trainee-led structured antibiotic time-outs to improve antimicrobial use. Ann Intern Med. 2014;161(10 Suppl):S53-S58.

Additional Practical Resources for Implementation

Recommended Stewardship Tools and Calculators

Antibiogram interpretation tools: Local susceptibility data should guide empiric therapy selection
Pharmacokinetic calculators: For vancomycin, aminoglycosides, and renally-eliminated agents
IDSA/SHEA Guidelines Repository: https://www.idsociety.org/practice-guideline/
CDC Core Elements Toolkit: Free implementation resources at https://www.cdc.gov/antibiotic-use/core-elements/hospital.html

Institutional Stewardship Metrics to Track

Process measures:
- DOT per 1,000 patient-days (overall and by antibiotic class)
- Proportion of empiric broad-spectrum regimens reassessed by 48-72 hours
- IV-to-PO conversion rate among eligible patients
- Compliance with guideline-recommended durations
Outcome measures:
- C. difficile infection rates
- Multidrug-resistant organism (MDRO) acquisition rates
- All-cause mortality (should not increase with effective stewardship)
- Length of stay
- Antibiotic-related adverse events

Building a Business Case for Stewardship

For hospitalists advocating for institutional stewardship resources:

Cost savings: Appropriate antibiotic use reduces drug costs, prevents C. difficile infections ($15,000-$30,000 per case), and decreases length of stay47
Regulatory requirements: The Joint Commission and CMS mandate antimicrobial stewardship programs as a condition of participation48
Medicolegal protection: Following evidence-based guidelines provides documentation of standard-of-care practice
Quality metrics: Many payers now tie reimbursement to stewardship metrics and infection prevention

Future Directions: Emerging Stewardship Opportunities

1. Post-Discharge Stewardship

Recent data demonstrate that 30-50% of antibiotic prescriptions at hospital discharge are longer than necessary.49 Hospitalists should:

Document the planned TOTAL duration (not just "discharge on X for 10 days")
Communicate clearly with outpatient providers about the rationale and end date
Consider "auto-stop" prescriptions that terminate on a specific date

Example discharge summary language:
"Completed 5 days of IV ceftriaxone for E. coli bacteremia (source: UTI). Transitioned to PO ciprofloxacin on discharge to complete 7-day TOTAL course. STOP DATE: [specific date]. Do not refill beyond this date unless clinical deterioration."

2. Rapid Diagnostics Integration

Molecular diagnostics (e.g., PCR panels for respiratory pathogens, blood culture rapid ID/AST) can accelerate de-escalation:

Positive respiratory viral PCR → discontinue antibacterial therapy in appropriate clinical contexts
Blood culture rapid MRSA PCR negative at 24 hours → discontinue vancomycin
Rapid AST → narrow to targeted agent 24-48 hours earlier than traditional methods

Hospitalists should partner with microbiology labs to understand turnaround times and create protocols for acting on rapid diagnostic results.

3. Antibiotic "Time-Outs"

Modeled after surgical time-outs, structured antibiotic time-outs at 48-72 hours involve the entire care team and have been shown to improve stewardship compliance by 30-40%.50 Key components:

Pause for 2-3 minutes during rounds
Review indication, cultures, clinical response, and planned duration
Document team consensus on continued need

4. Stewardship in the Age of Artificial Intelligence

Emerging AI-driven clinical decision support tools can:

Flag patients on prolonged courses who meet criteria for discontinuation
Predict antimicrobial resistance patterns to guide empiric therapy
Identify discordant therapy (continued vancomycin despite negative MRSA screens)

Hospitalists should engage with hospital informatics teams to pilot and validate these technologies.

Final Thoughts: The Stewardship Mindset

Effective antimicrobial stewardship requires a fundamental shift in prescribing culture—from defensive medicine ("cover everything, just in case") to evidence-based precision ("treat what's likely, narrow what's known, stop when appropriate").

This is not about rationing antibiotics or compromising patient care. Rather, it is the recognition that every antibiotic carries risk—individual risk (drug toxicity, C. difficile, selection of resistance) and societal risk (ecological pressure on our shared microbial environment).

As hospitalists managing the sickest patients during their most vulnerable moments, we must be stewards in the truest sense: caretakers of a precious resource that we hold in trust for future generations.

The stewardship mindset asks at every decision point:

Is this antibiotic necessary?
Is this the narrowest effective spectrum?
Is this the optimal route and dose?
When will I reassess?
When will I stop?

These questions, asked consistently and answered with evidence, define excellence in hospital medicine.

Acknowledgments

The authors acknowledge the global antimicrobial stewardship community whose dedication to preserving antibiotic effectiveness has generated the evidence base for this review. We thank the hospitalists, pharmacists, nurses, and microbiologists on the front lines who practice stewardship daily, often without recognition.

Disclosure Statement

The authors report no conflicts of interest relevant to this article.

Author Contributions

Manuscript concept, literature review, drafting, and critical revision were performed by the author. The author takes full responsibility for the content.

CME Questions (For Journal Submission)

Question 1: According to current IDSA/ATS guidelines, what is the recommended minimum duration of antibiotic therapy for uncomplicated community-acquired pneumonia in a clinically stable patient?

A) 3 days
B) 5 days
C) 7 days
D) 10 days

Answer: B (5 days for patients who are afebrile ≥48 hours with improving symptoms and no more than one CAP-associated sign of instability)

Question 2: Which of the following oral antibiotics has bioavailability >90% and can be considered equivalent to IV administration for most indications?

A) Cephalexin
B) Amoxicillin
C) Linezolid
D) Dicloxacillin

Answer: C (Linezolid has ~100% bioavailability; beta-lactams have variable and generally lower bioavailability)

Question 3: In the BALANCE trial, what was the demonstrated safe duration for uncomplicated Gram-negative bacteremia with documented source control?

A) 3 days
B) 7 days
C) 10 days
D) 14 days

Answer: B (7 days was non-inferior to 14 days for uncomplicated GNR bacteremia)

Question 4: What is the minimum recommended duration for Staphylococcus aureus bacteremia without endocarditis or complicated infection?

A) 7 days
B) 10 days
C) 14 days
D) 21 days

Answer: C (14 days is the minimum; 4-6 weeks required for endocarditis or complicated infections)

Word Count: ~8,500 words

Target Journal: Clinical Infectious Diseases, Journal of Hospital Medicine, Open Forum Infectious Diseases

Teaching Points for Postgraduate Learners

Case-Based Application Exercise

Case: A 68-year-old woman with COPD is admitted with fever, productive cough, and infiltrate on chest X-ray. Blood cultures drawn. Started on ceftriaxone 1g IV daily + azithromycin 500mg IV daily for severe CAP.

Day 1: Febrile to 38.9°C, tachypneic, on 4L NC, WBC 16,000
Day 3: Afebrile × 24h, oxygen requirement down to 2L, WBC 11,000, blood cultures negative × 48h, S. pneumoniae urinary antigen positive

Stewardship Questions:

Can you stop azithromycin? Yes—typical pathogen identified, clinically improving
Can you convert ceftriaxone IV to PO? Yes—meets the 3 A's (afebrile, able to take PO, awake)
What PO option? Amoxicillin 1g TID or cefpodoxime 200mg BID
What total duration? 5 days total (Day 3 + 2 more days = 5 days)
Can you stop vancomycin if it was started empirically? Yes—MRSA coverage not indicated for CAP with identified typical pathogen

This single case demonstrates multiple stewardship principles in action.

This comprehensive review provides postgraduate critical care trainees with both the evidence base and practical tools to implement antimicrobial stewardship as a core component of clinical excellence. The integration of pearls, oysters, and hacks—combined with specific communication strategies—equips hospitalists to navigate the complex interpersonal and clinical challenges of modern antimicrobial prescribing.

The Dyspneic Patient with a Clear Chest X-Ray

The Dyspneic Patient with a Clear Chest X-Ray: A Critical Care Perspective

Dr Neeraj Manikath , claude.ai

Abstract

Dyspnea with a clear chest radiograph represents a diagnostic challenge in critical care medicine, often leading to delayed diagnosis and suboptimal management. This clinical scenario demands a systematic approach beyond traditional imaging-based algorithms. This review explores the major differential diagnoses, emphasizing pulmonary embolism, metabolic acidosis, cardiac causes, neuromuscular weakness, and less common pulmonary etiologies. We provide evidence-based diagnostic strategies, clinical pearls, and practical approaches for the busy intensivist managing these complex patients.

Keywords: Dyspnea, normal chest radiograph, pulmonary embolism, metabolic acidosis, diastolic heart failure, neuromuscular weakness

Introduction

The complaint of dyspnea accounts for approximately 3-4% of emergency department visits and represents one of the most common reasons for ICU admission.[1] While chest radiography remains the initial imaging modality for evaluating dyspneic patients, up to 15-20% of patients with significant cardiopulmonary pathology present with normal or near-normal chest X-rays.[2] This clinical scenario can mislead even experienced clinicians, as our diagnostic algorithms are heavily weighted toward radiographic findings.

Pearl #1: Remember the "invisible lung diseases"—pulmonary embolism, early interstitial lung disease, pulmonary hypertension, and diastolic heart failure can all present with completely normal chest radiographs despite significant pathophysiology.

The systematic approach to dyspnea with a clear chest X-ray requires integration of clinical history, vital signs, physical examination, arterial blood gas analysis, electrocardiography, and targeted laboratory investigations. This review provides a structured framework for this challenging clinical presentation.

The Top of the List: Pulmonary Embolism

Epidemiology and Clinical Significance

Pulmonary embolism (PE) affects approximately 600,000 patients annually in the United States, with mortality rates ranging from 2-10% depending on hemodynamic stability.[3] The chest radiograph is normal or shows only nonspecific findings in 12-33% of PE cases.[4] This makes PE a critical "can't miss" diagnosis in patients with dyspnea and clear chest imaging.

Clinical Presentation

The classic triad of dyspnea, pleuritic chest pain, and hemoptysis occurs in fewer than 20% of cases.[5] More commonly, patients present with:

Acute onset dyspnea (73-85%)
Tachypnea (>20 breaths/min in 70%)
Tachycardia (>100 bpm in 40%)
Pleuritic chest pain (44-66%)
Hypoxemia (though normal PaO2 doesn't exclude PE)

Pearl #2: The most sensitive single finding for PE is tachypnea—if your dyspneic patient has a respiratory rate <20/min, reconsider the diagnosis.

Oyster #1: Don't be fooled by normal oxygen saturation. Up to 30% of patients with confirmed PE have SpO2 >95% on room air, particularly younger patients without comorbidities.[6]

Diagnostic Approach: Wells Score and PERC Rule

The Wells Score for PE

The Wells score remains the most widely validated clinical decision rule for PE risk stratification (Table 1).[7]

Table 1: Wells Score for Pulmonary Embolism

Clinical Feature	Points
Clinical signs of DVT	3.0
PE most likely diagnosis	3.0
Heart rate >100 bpm	1.5
Immobilization ≥3 days or surgery in previous 4 weeks	1.5
Previous PE/DVT	1.5
Hemoptysis	1.0
Malignancy (active or within 6 months)	1.0

Interpretation:

Score ≤4: PE unlikely (prevalence ~10%)
Score >4: PE likely (prevalence ~40%)

The Wells score should be applied using the two-tier system. A dichotomized approach (likely vs. unlikely) has been shown to be more practical than three-tier risk stratification in most settings.[8]

Hack #1: The "PE is the most likely diagnosis" criterion is subjective but powerful. If after your initial assessment you cannot come up with a more likely explanation for the presentation, assign these 3 points. Don't let diagnostic uncertainty prevent you from using this tool.

The Pulmonary Embolism Rule-Out Criteria (PERC)

The PERC rule is designed to identify very low-risk patients who do not require D-dimer testing or imaging.[9] All eight criteria must be absent to apply PERC:

Age <50 years
Heart rate <100 bpm
SpO2 ≥95% on room air
No hemoptysis
No estrogen use
No prior PE/DVT
No unilateral leg swelling
No surgery/trauma requiring hospitalization within 4 weeks

Pearl #3: PERC should only be applied to patients with LOW pre-test probability. Using PERC in higher-risk patients increases missed diagnoses. The proper sequence is: Clinical gestalt → If low suspicion, apply PERC → If PERC negative, no further testing needed.

A prospective study of 8,138 patients demonstrated that PERC-negative patients had a 3-month thromboembolic event rate of only 1.0%, making it safe to withhold further testing in this group.[10]

D-Dimer Testing

D-dimer remains a highly sensitive but poorly specific marker for PE. Key considerations include:

Age-adjusted D-dimer cutoffs: For patients >50 years, use age × 10 μg/L as the cutoff (e.g., 700 μg/L for a 70-year-old). This approach increases specificity from 34% to 46% in elderly patients while maintaining 97% sensitivity.[11]

Oyster #2: D-dimer is useless in most ICU patients. Elevated D-dimer occurs with sepsis, DIC, recent surgery, pregnancy, cancer, renal failure, and inflammatory conditions. In critically ill patients with high pre-test probability, proceed directly to imaging rather than checking D-dimer.

Definitive Diagnosis: CTPA

CT pulmonary angiography (CTPA) is the gold standard diagnostic test, with sensitivity of 83-96% and specificity of 89-96%.[12] Modern multidetector CT can visualize emboli to the subsegmental level, though the clinical significance of isolated subsegmental PE remains debated.

Hack #2: For hemodynamically unstable patients too sick to travel to CT, consider bedside echocardiography looking for right ventricular strain (RV/LV ratio >0.9, McConnell's sign, septal flattening) or lower extremity venous ultrasound. Finding proximal DVT in a patient with unexplained shock is sufficient to initiate anticoagulation without CTPA.

Management Pearls

For hemodynamically stable PE:

Direct oral anticoagulants (DOACs) are now first-line therapy (apixaban, rivaroxaban) with equal efficacy and better safety profiles compared to warfarin[13]
Low-risk PE may be managed as outpatients using PESI or sPESI scores

For massive or submassive PE:

Thrombolysis reduces mortality in hemodynamically unstable PE (NNT ~6)[14]
Consider catheter-directed therapies for submassive PE with RV dysfunction if bleeding risk is high
Extracorporeal membrane oxygenation (ECMO) should be considered for refractory shock

Metabolic Acidosis: Kussmaul's Respirations and Beyond

Pathophysiology

Metabolic acidosis triggers respiratory compensation through central and peripheral chemoreceptor stimulation. Kussmaul respirations—deep, labored breathing at a normal or increased rate—represent the body's attempt to eliminate CO2 and normalize pH. The respiratory system can compensate rapidly, with the expected PaCO2 calculated by Winter's formula:

Expected PaCO2 = (1.5 × HCO3) + 8 ± 2

Pearl #4: Always calculate the expected compensation. If the measured PaCO2 is higher than expected, there's a concomitant respiratory acidosis. If lower, there's a concurrent respiratory alkalosis or the patient is overcompensating (rare).

Diabetic Ketoacidosis (DKA)

DKA remains the most common cause of severe metabolic acidosis presenting with dyspnea and clear chest imaging. The diagnostic triad includes:

Hyperglycemia (typically >250 mg/dL, though euglycemic DKA occurs with SGLT2 inhibitors)
Anion gap metabolic acidosis (pH <7.3, HCO3 <18 mEq/L)
Ketonemia or ketonuria

Hack #3: Calculate the anion gap (AG = Na - [Cl + HCO3], normal 8-12) AND the delta gap (ΔAG/ΔHCO3 ratio). A ratio of ~1 suggests pure AG acidosis. A ratio >2 suggests concurrent metabolic alkalosis (vomiting, diuretics), while <1 suggests concurrent non-AG acidosis (diarrhea, RTA).

Other Causes of High Anion Gap Metabolic Acidosis (GOLD MARK)

Glycolate (ethylene glycol)
Oxoproline (chronic acetaminophen use)
L-lactate (tissue hypoxia, sepsis, metformin)
D-lactate (short bowel syndrome)
Methanol
Aspirin (salicylates)
Renal failure (uremia)
Ketones (DKA, alcoholic ketoacidosis, starvation)

Pearl #5: In alcoholic ketoacidosis, glucose is typically normal or low (unlike DKA), and beta-hydroxybutyrate is elevated out of proportion to acetoacetate. Urine ketone dipsticks may be falsely negative because they detect acetoacetate preferentially.

Oyster #3: Severe lactic acidosis (lactate >15-20 mmol/L) with dyspnea and clear chest X-ray should raise suspicion for metformin toxicity, especially in patients with renal impairment. Hemodialysis effectively clears both metformin and lactate.[15]

Diagnostic Approach

Obtain arterial blood gas with co-oximetry (to detect methemoglobinemia, carboxyhemoglobinemia)
Calculate anion gap and delta gap
Measure serum osmolar gap if toxic alcohol ingestion suspected: Osmolar gap = Measured osmolality - Calculated osmolality (2×Na + glucose/18 + BUN/2.8)
Check lactate, ketones, renal function, salicylate level as indicated
Evaluate for tissue hypoxia if lactic acidosis present (sepsis, shock, bowel ischemia)

Management Considerations

Treat the underlying cause—insulin for DKA, fomepizole for toxic alcohols, source control for septic shock
Bicarbonate therapy is controversial. Consider for pH <7.1 in DKA (though not routinely recommended) or pH <7.2 in other causes
Avoid respiratory fatigue—patients with severe acidosis performing significant respiratory work may need mechanical ventilation before developing hypercapnia

Hack #4: When intubating patients with metabolic acidosis, match the minute ventilation to their pre-intubation effort (often 15-20 L/min). Inadequate ventilation post-intubation can cause precipitous pH drops and cardiovascular collapse. Calculate: Minute ventilation = RR × Vt × (PaCO2 40/PaCO2 current).

Cardiac Causes: The Invisible Heart Failure

Diastolic Heart Failure (HFpEF)

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of heart failure cases and is dramatically underdiagnosed.[16] These patients can present with severe dyspnea yet have completely normal chest radiographs between episodes of decompensation.

Pathophysiology

HFpEF results from impaired left ventricular relaxation and increased chamber stiffness, leading to elevated filling pressures without reduced systolic function. Risk factors include:

Hypertension (present in >90%)
Diabetes mellitus
Obesity
Atrial fibrillation
Chronic kidney disease
Age >65 years

Pearl #6: The HFpEF patient's chest X-ray may be clear in the ICU because they've received diuretics in the ED. Ask about fluid administration and initial presentation—pulmonary edema that rapidly responds to diuretics is classic for HFpEF.

Clinical Diagnosis

The H2FPEF score helps identify HFpEF likelihood (score 0-9):[17]

Heavy (BMI >30): 2 points
Hypertension (≥2 antihypertensives): 1 point
Atrial Fibrillation: 3 points
Pulmonary hypertension (PASP >35 mmHg): 1 point
Elder (age >60): 1 point
Filling pressure (E/e' >9): 1 point

Score ≥6 indicates high probability of HFpEF (>90% likelihood).

Diagnostic Investigations

Brain natriuretic peptide (BNP): BNP >100 pg/mL or NT-proBNP >300 pg/mL supports heart failure diagnosis, though levels may be lower in obesity and chronic HF[18]
Echocardiography: Key findings include:
- Preserved LVEF (>50%)
- Left atrial enlargement (LA volume index >34 mL/m²)
- Elevated E/e' ratio (>14, or >8 with other criteria)
- Elevated tricuspid regurgitation velocity
Diastolic stress test: May demonstrate exercise-induced elevation in filling pressures

Oyster #4: Don't be reassured by "normal" BNP in obese patients. Adipose tissue expresses natriuretic peptide clearance receptors, leading to falsely low levels. An NT-proBNP <100 pg/mL in an obese patient with dyspnea makes HFpEF unlikely, but levels 100-300 pg/mL are indeterminate.

Hack #5: Bedside ultrasound can rapidly assess for HFpEF: Look for B-lines (indicating interstitial edema), dilated IVC with reduced respiratory variation (>2.1 cm with <50% collapse), and E/e' ratio. Even without formal echo training, the presence of multiple B-lines in a dyspneic patient with clear CXR should prompt consideration of HFpEF.

Valvular Heart Disease

Mitral Stenosis

Mitral stenosis (MS), typically rheumatic in origin, causes elevated left atrial pressures and dyspnea but may present with clear chest radiographs, especially in mild-moderate disease.

Key examination findings:

Opening snap after S2
Diastolic rumble at apex, accentuated by expiration and left lateral position
Loud S1 (early MS) or soft S1 (severe MS with calcification)

Pearl #7: The interval between A2 (aortic closure) and the opening snap correlates inversely with severity—a shorter interval indicates higher left atrial pressure and more severe stenosis.

Echocardiography confirms diagnosis (severe MS defined as valve area <1.0 cm²).

Aortic Stenosis

Severe aortic stenosis (AS) can present with exertional dyspnea, angina, or syncope—the classic triad. Chest X-ray may be normal until late-stage disease develops.

Physical examination reveals:

Crescendo-decrescendo systolic murmur at right upper sternal border radiating to carotids
Delayed, diminished carotid upstroke (pulsus parvus et tardus)
Paradoxical splitting of S2 (severe AS)

Oyster #5: Low-gradient, low-EF aortic stenosis is a diagnostic pitfall. Patients with poor LV function may not generate sufficient flow across a severely stenotic valve to produce a loud murmur or high gradient on Doppler. Don't be falsely reassured by a "soft murmur" in a patient with cardiomyopathy.

Diagnosis requires echocardiography (severe AS: valve area <1.0 cm², mean gradient >40 mmHg, or peak velocity >4 m/s).

Management Pearls for Cardiac Causes

HFpEF Management:

Diuretics for volume overload (first-line symptom management)
SGLT2 inhibitors (dapagliflozin, empagliflozin) reduce HF hospitalizations and improve quality of life[19]
Tight BP control (target <130/80 mmHg)
Treat atrial fibrillation with rate control
Avoid excessive diuresis (these patients are preload-dependent)

Valvular Disease:

MS: Rate control crucial for adequate diastolic filling time; anticoagulation for AF
AS: Avoid aggressive afterload reduction and excessive diuresis (preload-dependent); aortic valve replacement for symptomatic severe AS

Neuromuscular Weakness: When the Pump Fails

Neuromuscular causes of dyspnea are frequently overlooked because clinicians focus on cardiopulmonary pathology. These conditions produce restrictive respiratory failure with clear lungs on imaging.

Clinical Recognition

Red flag symptoms suggesting neuromuscular cause:

Orthopnea out of proportion to dyspnea (diaphragm weakness worsens supine)
Weak cough, inability to clear secretions
Dysphagia, dysarthria, ptosis, diplopia
Progressive symmetric weakness
Paradoxical abdominal breathing (abdomen moves inward with inspiration—a sign of diaphragm paralysis)

Pearl #8: The "single breath count test" is a simple bedside assessment. Ask the patient to take a deep breath and count as high as possible in one breath. Normal adults reach 30-50. Counts <15 suggest significant respiratory muscle weakness requiring close monitoring.

Myasthenia Gravis

Myasthenia gravis (MG) results from antibody-mediated blockade of acetylcholine receptors at the neuromuscular junction, causing fatigable weakness.

Clinical Presentation

Fluctuating weakness worsening with activity
Ocular symptoms (ptosis, diplopia) in 85%
Bulbar symptoms (dysphagia, dysarthria) in 60%
Respiratory crisis in 15-20% at some point

Myasthenic crisis is defined as respiratory failure requiring mechanical ventilation, often precipitated by infection, surgery, medication changes, or pregnancy.

Diagnosis

Bedside tests:
- Ice pack test: Apply ice to ptotic eyelid for 2 minutes; improvement suggests MG (sensitivity 80-92%)
- Edrophonium test (largely replaced by serology)
Serologic testing:
- Anti-acetylcholine receptor antibodies (85% sensitivity)
- Anti-MuSK antibodies (40% of seronegative cases)
- Anti-LRP4 antibodies (emerging biomarker)
Electrophysiology: Repetitive nerve stimulation showing >10% decrement is diagnostic
Respiratory function tests:
- Vital capacity (VC): <20 mL/kg predicts need for mechanical ventilation
- Negative inspiratory force (NIF): <-30 cm H2O indicates significant weakness
- Monitor trend rather than single values

Hack #6: The "20/30/40 rule" for intubation in myasthenic crisis: Consider mechanical ventilation if VC <20 mL/kg, NIF <30 cm H2O, OR maximum expiratory pressure <40 cm H2O. Don't wait for hypercapnia—by then the patient is exhausted.

Management

Acute treatment:

Plasmapheresis or IVIg (both equally effective; choose based on availability and contraindications)[20]
Continue anticholinesterase medications (pyridostigmine) but be cautious with excessive dosing (can cause cholinergic crisis)
Avoid neuromuscular blocking agents in intubated patients (extreme sensitivity)
Treat precipitating factors (infection, electrolyte abnormalities)

Medications to avoid in MG: Aminoglycosides, fluoroquinolones, beta-blockers, procainamide, quinine, magnesium

Guillain-Barré Syndrome

Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy, classically following infection (Campylobacter jejuni, CMV, EBV, Zika virus).

Clinical Features

Ascending symmetric weakness progressing over days to weeks
Areflexia or hyporeflexia
Minimal sensory involvement
Autonomic dysfunction (labile BP, arrhythmias) in 65%
Respiratory failure requiring mechanical ventilation in 25-30%

Pearl #9: Facial weakness and bulbar dysfunction are strong predictors of respiratory failure in GBS. The Erasmus GBS Respiratory Insufficiency Score (EGRIS) incorporates facial/bulbar weakness, time from onset to admission <7 days, and inability to stand as predictors of needing ventilation.[21]

Diagnosis

CSF analysis: Albumino-cytologic dissociation (elevated protein with normal cell count) is characteristic but may be absent in the first week.

EMG/NCS: Shows demyelinating or axonal neuropathy patterns.

Management

IVIg 0.4 g/kg/day for 5 days OR plasmapheresis (equally effective)[22]
Combination therapy offers no advantage
Monitor respiratory function closely (VC, NIF every 4-6 hours initially)
DVT prophylaxis (high risk due to immobility)
Consider temporary pacing for severe autonomic instability

Oyster #6: The "bifacial weakness with paresthesias" variant (Miller-Fisher syndrome) presents with ataxia, areflexia, and ophthalmoplegia. Anti-GQ1b antibodies are positive in 85%. These patients rarely require ventilation but need close monitoring.

Other Neuromuscular Causes

Phrenic nerve injury (post-cardiac surgery, mediastinal mass, iatrogenic): Consider if unilateral diaphragm elevation on CXR or ultrasound shows absent/paradoxical movement.

Amyotrophic lateral sclerosis (ALS): Progressive weakness with mixed upper and lower motor neuron signs; respiratory failure may be the presenting feature.

Critical illness polyneuropathy/myopathy: Develops in 25-80% of critically ill patients with sepsis, prolonged mechanical ventilation, or high-dose steroids; consider in difficult-to-wean patients.

The "Other" Pulmonary Causes

Interstitial Lung Disease (ILD)

Interstitial lung diseases encompass over 200 entities causing inflammation and fibrosis of the lung interstitium. Early disease may present with dyspnea and clear chest radiographs, though high-resolution CT (HRCT) typically reveals abnormalities.

Clinical Presentation

Progressive exertional dyspnea
Non-productive cough
Inspiratory crackles ("Velcro-like")
Digital clubbing (especially in idiopathic pulmonary fibrosis)

Pearl #10: The timing and character of crackles help differentiate ILD from heart failure. ILD crackles are fine, "dry," inspiratory, and heard at bases; they don't change with cough or position. CHF crackles are coarser, may be expiratory, and clear with diuresis.

Diagnostic Approach

PFTs: Restrictive pattern (FVC <80%, FEV1/FVC ratio normal or increased, reduced DLCO)
HRCT chest: The gold standard for ILD evaluation
Serology: ANA, RF, anti-CCP, myositis panel, hypersensitivity pneumonitis panel
Bronchoscopy with BAL: For differential cell counts, culture, malignancy
Surgical lung biopsy: Sometimes necessary for definitive diagnosis

Hack #7: If you suspect ILD but chest X-ray is clear, don't wait for HRCT. Check bedside lung ultrasound for B-lines and pleural irregularity. While not diagnostic, their presence increases probability and urgency of HRCT.

Management

Idiopathic pulmonary fibrosis (IPF): Antifibrotic therapy (pirfenidone or nintedanib) slows progression[23]
Connective tissue disease-associated ILD: Immunosuppression (mycophenolate, cyclophosphamide)
Hypersensitivity pneumonitis: Antigen avoidance, corticosteroids
Supplemental oxygen for hypoxemia
Pulmonary rehabilitation
Lung transplant evaluation for advanced disease

Pulmonary Hypertension

Pulmonary hypertension (PH) is defined as mean pulmonary artery pressure ≥20 mmHg at rest (updated from ≥25 mmHg in 2019).[24] Chest radiographs are often normal, especially in precapillary PH.

Clinical Presentation

Exertional dyspnea (cardinal symptom)
Fatigue, weakness
Exertional chest pain, syncope (advanced disease)
Symptoms of right heart failure (edema, ascites) late

Physical examination:

Accentuated P2 (pulmonary component of S2)
Right ventricular heave
Tricuspid regurgitation murmur
Elevated JVP

Pearl #11: A loud P2 that's palpable at the left upper sternal border is a specific (though insensitive) sign of pulmonary hypertension. Also listen for a Graham Steell murmur (early diastolic decrescendo murmur from pulmonary regurgitation).

Diagnosis

Echocardiography: Screening tool estimating PASP from tricuspid regurgitation velocity (TR jet >2.8 m/s suggests PASP >35 mmHg)
Right heart catheterization: Required for definitive diagnosis and classification
Workup for underlying etiology:
- Group 1 (PAH): Serologies, HIV, hepatitis, CT chest
- Group 2 (left heart disease): Echo, cardiac MRI
- Group 3 (lung disease): PFTs, HRCT
- Group 4 (CTEPH): V/Q scan (more sensitive than CTPA for chronic PE)
- Group 5 (multifactorial)

Oyster #7: V/Q scanning is MORE sensitive than CTPA for chronic thromboembolic pulmonary hypertension (CTEPH). If you suspect CTEPH, order V/Q first. A "low probability" V/Q scan effectively rules out CTEPH, while any perfusion defects warrant further evaluation.

Management

Highly specialized and depends on PH group:

PAH (Group 1): Calcium channel blockers (if vasoreactive), phosphodiesterase-5 inhibitors, endothelin receptor antagonists, prostacyclins
Group 2: Optimize left heart failure management
Group 3: Treat underlying lung disease, supplemental oxygen
CTEPH (Group 4): Pulmonary endarterectomy (potentially curative!) or balloon pulmonary angioplasty
All groups: Supplemental oxygen, diuretics for fluid overload, anticoagulation (controversial, patient-specific)

Anemia

Severe anemia (Hb <7-8 g/dL) commonly causes dyspnea via reduced oxygen-carrying capacity, though patients with chronic anemia may be asymptomatic until Hb drops below 5-6 g/dL due to compensatory mechanisms.

Pathophysiology of Dyspnea in Anemia

Reduced oxygen delivery to tissues
Compensatory increase in cardiac output (high-output state)
Leftward shift of oxygen-hemoglobin dissociation curve (if concurrent alkalosis)
Tissue hypoxia triggers respiratory drive

Pearl #12: Dyspnea from anemia is typically exertional with preserved oxygen saturation (the pulse oximeter measures the percentage of hemoglobin that's saturated, not oxygen-carrying capacity). If SpO2 is low, look for another cause.

Diagnostic Considerations

The patient's story guides workup:

Acute blood loss: Trauma, GI bleeding, ruptured AAA, ectopic pregnancy
Hemolysis: Jaundice, elevated bilirubin/LDH, low haptoglobin, schistocytes
Bone marrow suppression: Chemotherapy, aplastic anemia, malignancy
Nutritional deficiency: Iron, B12, folate (usually chronic)
Chronic disease: Inflammatory conditions, CKD

Management

Transfusion: Liberal threshold (Hb <10 g/dL) for acute coronary syndrome, symptomatic patients; restrictive threshold (Hb <7-8 g/dL) for most others[25]
Treat underlying cause: Iron supplementation, B12/folate replacement, erythropoietin for CKD, cessation of offending drugs
Supplemental oxygen: May be needed temporarily for symptomatic relief despite normal saturation

Hack #8: Calculate oxygen delivery (DO2 = CO × CaO2, where CaO2 = [1.34 × Hb × SaO2] + [0.003 × PaO2]). In anemic patients, small increases in cardiac output or saturation significantly impact oxygen delivery. A patient with Hb 7 g/dL who desaturates from 98% to 92% loses 13% of oxygen delivery—much more impactful than in a patient with normal Hb.

A Systematic Diagnostic Framework

Given the broad differential diagnosis, a systematic approach is essential:

Step 1: Immediate Assessment

Vital signs: Tachypnea? Hypoxia? Hypotension? Fever?
Work of breathing: Accessory muscle use, paradoxical breathing, single breath count
Cardiovascular: JVP, heart sounds, peripheral perfusion

Step 2: Focused History

Tempo: Acute (<24h), subacute (days-weeks), or chronic (months)?
Triggers: Exertion, position, exposure?
Associated symptoms: Chest pain, leg swelling, weakness, weight loss?
Risk factors: Immobility, cancer, pregnancy, recent surgery, autoimmune disease?

Step 3: Key Investigations

ABG: pH, PaCO2, PaO2, A-a gradient, lactate
ECG: RV strain, ischemia, arrhythmia
Laboratory: CBC, BMP, troponin, BNP, D-dimer (if PE possible)
Chest X-ray: Confirm truly clear
Echocardiography: Early if cardiac cause suspected
CT pulmonary angiography: If Wells score positive or high suspicion

Hack #9: Calculate the A-a gradient: A-a = [FiO2 × (Patm - PH2O) - PaCO2/RQ] - PaO2, which simplifies to A-a = [150 - PaCO2/0.8] - PaO2 on room air at sea level. Normal is <10-15 mmHg (increases with age: Age/4 + 4). An elevated A-a gradient suggests V/Q mismatch (PE, shunt), while a normal A-a with hypoxemia suggests hypoventilation (neuromuscular weakness, metabolic alkalosis, drug overdose).

Step 4: Pattern Recognition

Clinical Pattern	Key Features	First Test
Sudden onset, pleuritic pain, risk factors	PE	Wells + CTPA
Deep rapid breathing, Kussmaul pattern	Metabolic acidosis	ABG
Orthopnea, edema, history of HTN	HFpEF	BNP + Echo
Ptosis, weak cough, fatigable weakness	MG	NIF/VC + AChR Ab
Ascending weakness, areflexia	GBS	CSF + EMG
Chronic progressive, dry cough, crackles	ILD	HRCT + PFTs
Exertional syncope, loud P2	PH	Echo + RHC

Special Populations and Clinical Scenarios

The Pregnant Patient with Dyspnea and Clear CXR

Pregnancy produces physiological changes that complicate dyspnea evaluation:

Physiological adaptations:

Increased minute ventilation (30-50%) due to progesterone-mediated respiratory drive
Chronic respiratory alkalosis (PaCO2 28-32 mmHg, compensated with HCO3 18-21 mEq/L)
Plasma volume expansion causing "physiological anemia" (Hb 10-11 g/dL)
Decreased functional residual capacity (20%) due to diaphragm elevation

Pearl #13: Up to 75% of pregnant women report dyspnea at some point, typically beginning in the first or second trimester. However, new or worsening dyspnea in the third trimester should never be dismissed as "normal pregnancy."

High-risk diagnoses in pregnancy:

Pulmonary embolism: 5-fold increased risk; leading cause of maternal mortality in developed countries[26]
- Modified Wells score and D-dimer still useful (though D-dimer progressively increases through pregnancy)
- CTPA is safe and preferred over V/Q scanning (lower fetal radiation exposure)
Peripartum cardiomyopathy: Occurs in last month of pregnancy through 5 months postpartum
- Presents with heart failure symptoms, often clear CXR initially
- Echo shows LV systolic dysfunction (EF <45%)
- Treatment: Standard heart failure therapy; bromocriptine shows promise[27]
Amniotic fluid embolism: Rare but catastrophic, typically during labor/delivery
- Sudden dyspnea, hypoxia, hypotension, DIC
- Diagnosis of exclusion; supportive care

Hack #10: When ordering CTPA in pregnancy, communicate with radiology to optimize technique: scan during end-inspiration (reduces breast dose), use lower contrast dose timed to peak pulmonary artery enhancement. Fetal radiation exposure is minimal (<0.1 mGy) and should not delay necessary imaging.

The Post-Operative Patient

Post-operative dyspnea with clear imaging presents unique considerations:

Common causes:

Atelectasis: May not be visible on CXR initially; consider incentive spirometry and mobilization
PE: Major surgery is a significant risk factor; maintain high suspicion days 3-7 post-op
Fluid overload: Especially with diastolic dysfunction; BNP may be less reliable post-operatively
Neuromuscular weakness: Residual anesthetic effects, critical illness polyneuropathy
Anxiety/pain: Often overlooked; inadequate analgesia increases work of breathing

Pearl #14: Post-cardiac surgery patients with unexplained dyspnea should have phrenic nerve function assessed (diaphragm ultrasound or fluoroscopy). Phrenic nerve injury occurs in 10-20% of cardiac surgeries due to cold cardioplegia or surgical trauma, causing unilateral diaphragm paralysis.

The Immunocompromised Patient

HIV/AIDS, transplant recipients, and patients on immunosuppression present diagnostic challenges:

Expanded differential includes:

Pneumocystis jirovecii pneumonia (PCP): May have subtle or absent CXR findings early; elevated LDH, reduced DLCO, and desaturation with exertion are clues; induced sputum or BAL for diagnosis
Cytomegalovirus pneumonitis: Particularly in transplant recipients
Pulmonary Kaposi sarcoma: In advanced HIV; endobronchial lesions visible on bronchoscopy
Immune reconstitution inflammatory syndrome (IRIS): After initiating antiretroviral therapy
Drug-induced pneumonitis: Methotrexate, checkpoint inhibitors, many others

Hack #11: In an HIV patient with dyspnea and clear CXR, check CD4 count, LDH, and exercise oximetry. If CD4 <200, LDH >500, and desaturation >5% with exertion, PCP likelihood is >80%. Initiate empiric treatment and pursue bronchoscopy urgently.

Advanced Diagnostic Techniques

Point-of-Care Ultrasound (POCUS)

Bedside ultrasound has revolutionized dyspnea evaluation. The BLUE protocol (Bedside Lung Ultrasound in Emergency) provides a systematic approach:[28]

Lung zones: Examine anterior, lateral, and posterolateral chest bilaterally

Key findings:

A-lines (horizontal artifacts): Normal aerated lung
B-lines (vertical artifacts): Interstitial syndrome (pulmonary edema, ILD, ARDS)
- 3 B-lines per intercostal space = significant
- Bilateral, symmetric B-lines suggest cardiogenic pulmonary edema
- Asymmetric/patchy B-lines suggest pneumonia or ILD
Consolidation: Hepatization of lung (pneumonia, atelectasis, infarction)
Pleural sliding: Absent with pneumothorax
Pleural effusion: Anechoic space above diaphragm

Cardiac ultrasound findings:

LV function assessment (eyeball EF)
RV dilation and strain (RV:LV ratio >1, D-shaped septum → PE or PH)
IVC diameter and collapsibility (<50% collapse suggests elevated CVP)
Pericardial effusion with tamponade physiology

Vascular ultrasound:

DVT evaluation (femoral and popliteal veins)
Non-compressible vein = thrombus

Pearl #15: The FALLS protocol (Fluid Administration Limited by Lung Sonography) can guide fluid management in shock: if B-lines appear during fluid resuscitation, stop fluids and consider inotropes/vasopressors. This prevents iatrogenic pulmonary edema in patients with diastolic dysfunction.[29]

Cardiopulmonary Exercise Testing (CPET)

For chronic dyspnea with normal resting tests, CPET provides objective assessment of exercise capacity and helps differentiate cardiac, pulmonary, and deconditioning causes:

Key measurements:

VO2 max: Maximal oxygen consumption
Anaerobic threshold: Point where lactate accumulates
VE/VCO2 slope: Ventilatory efficiency (elevated in heart failure, PH)
Breathing reserve: [(MVV - peak VE)/MVV] × 100; <15% suggests ventilatory limitation
Heart rate reserve: Failure to achieve predicted max HR suggests chronotropic incompetence

Pattern recognition:

Cardiac limitation: Low VO2 max, high VE/VCO2 slope, low O2 pulse
Pulmonary limitation: Low breathing reserve, desaturation, normal VE/VCO2
Deconditioning: Low VO2 max, normal VE/VCO2, adequate breathing reserve, early anaerobic threshold
Pulmonary vascular disease: High VE/VCO2, low end-tidal CO2, desaturation

Oyster #8: A normal CPET doesn't exclude all pathology but does suggest symptoms are out of proportion to physiological impairment. Consider anxiety, hyperventilation syndrome, or dysfunctional breathing patterns.

Advanced Laboratory Testing

Methemoglobin and Carboxyhemoglobin:

Require co-oximetry (not measured by standard pulse oximetry)
Methemoglobinemia causes dyspnea with "chocolate-colored" blood, SpO2 fixed at ~85%
Causes: dapsone, benzocaine, nitrites, sulfonamides
Treatment: Methylene blue 1-2 mg/kg IV

Hemoglobin electrophoresis:

Consider in unexplained cyanosis or dyspnea in appropriate ethnic populations
Sickle cell disease, thalassemia, unstable hemoglobins

Autoimmune panel:

ANA, dsDNA, anti-Ro, anti-La (SLE)
Anti-Scl-70, anti-centromere (scleroderma with ILD)
Anti-Jo-1, anti-synthetase antibodies (polymyositis/dermatomyositis with ILD)
ANCA (granulomatosis with polyangiitis causing pulmonary hemorrhage)

Pitfalls and Mimics

Anxiety and Hyperventilation Syndrome

True dyspnea vs. hyperventilation: While anxiety can cause subjective breathlessness, be cautious about attributing dyspnea to anxiety without thorough evaluation. Patients with PE, MI, and other life-threatening conditions are often anxious.

Features suggesting hyperventilation syndrome:

Paresthesias (perioral, digital)
Carpopedal spasm
Chest tightness without pain
Respiratory alkalosis on ABG without compensation
Normal A-a gradient
Symptoms reproduced by voluntary hyperventilation

Pearl #16: The Nijmegen questionnaire can help identify hyperventilation syndrome, but organic disease must be excluded first. Patients can have both anxiety AND serious pathology—don't anchor on the psychiatric explanation.

Hack #12: If hyperventilation syndrome is suspected, have the patient breathe into a paper bag briefly (not prolonged—dangerous if wrong diagnosis!). Symptom improvement suggests hyperventilation, though this test is controversial and should not replace thorough workup.

Vocal Cord Dysfunction (VCD)

VCD, also called paradoxical vocal fold motion, causes dyspnea and wheeze due to inappropriate vocal cord adduction during inspiration.

Clinical features:

Inspiratory stridor or wheeze (vs. expiratory in asthma)
Sudden onset and resolution
Throat tightness, voice changes
Refractory to bronchodilators
Often misdiagnosed as asthma

Diagnosis: Laryngoscopy during symptomatic episode showing paradoxical vocal cord movement

Treatment: Speech therapy, breathing exercises, treatment of triggers (GERD, rhinosinusitis)

Deconditioning

In the modern ICU, prolonged bedrest causes rapid deconditioning that manifests as dyspnea:

Physiological changes:

10-15% loss of muscle strength per week of bedrest
Reduced VO2 max (15% in first week)
Reduced cardiac output with exertion
Ventilatory muscle weakness

Recognition: Dyspnea with minimal exertion (sitting up, standing) in patient with prolonged critical illness but no acute cardiopulmonary pathology

Management: Early mobilization, physical therapy, pulmonary rehabilitation

Management Principles and ICU Considerations

Initial Stabilization

The ABCs remain paramount:

Airway: Assess patency, ability to protect airway
Breathing: Supplemental oxygen, non-invasive ventilation if needed
Circulation: IV access, monitor hemodynamics

When to intubate: Clinical judgment, but consider:

Respiratory rate >40 or increasing trend
Accessory muscle use, paradoxical breathing
Inability to speak in full sentences
Altered mental status
Progressive hypoxemia despite supplemental oxygen
Impending respiratory arrest

Pearl #17: In patients with metabolic acidosis or neuromuscular weakness, intubation decision should be made BEFORE hypercapnia develops. By the time CO2 is rising, respiratory muscles are exhausted. Use clinical assessment of work of breathing, not just ABG.

Non-Invasive Ventilation (NIV)

Appropriate candidates:

Acute cardiogenic pulmonary edema (reduces intubation rate, mortality)[30]
Acute hypercapnic respiratory failure in COPD
Immunocompromised patients with acute respiratory failure (reduces intubation, mortality)
Facilitating extubation in high-risk patients

Contraindications:

Hemodynamic instability, arrhythmias
Inability to protect airway
Recent upper GI surgery
Uncooperative patient
Copious secretions

Settings:

CPAP: 5-10 cm H2O (primarily for pulmonary edema)
BiPAP: IPAP 10-20, EPAP 5-10 (titrate to patient comfort and gas exchange)

Hack #13: Start with lower pressures and gradually increase. Patient tolerance is key—an uncomfortable patient won't keep the mask on. Use heated humidification to improve comfort. Reassess frequently in first 1-2 hours; if not improving, don't delay intubation.

High-Flow Nasal Cannula (HFNC)

HFNC delivers heated, humidified oxygen at flows up to 60 L/min, providing:

Washout of nasopharyngeal dead space
Modest PEEP (3-5 cm H2O)
Improved mucociliary function
Better tolerance than NIV

Pearl #18: HFNC is particularly useful when you're uncertain about the diagnosis and need time for workup. It's better tolerated than NIV, allows the patient to eat/drink/speak, and buys time for investigations while providing respiratory support.

ROX index predicts HFNC success: (SpO2/FiO2) / Respiratory Rate

ROX >4.88 at 12 hours predicts low risk of intubation
ROX <3.85 predicts high risk of failure; consider early intubation[31]

Mechanical Ventilation Strategies

For PE patients:

Minimize plateau pressures (<30 cm H2O)
Avoid high PEEP (impairs RV function)
Keep pH >7.2 (respiratory acidosis worsens pulmonary vasoconstriction)
Consider inhaled pulmonary vasodilators (nitric oxide, epoprostenol)
Prone positioning if severe ARDS develops

For metabolic acidosis:

Match pre-intubation minute ventilation (often requires RR 20-30, Vt 6-8 mL/kg)
Monitor post-intubation pH closely
May need bicarbonate infusion to prevent cardiovascular collapse
Prepare vasopressors before intubation

For neuromuscular weakness:

Avoid neuromuscular blocking agents if possible
If paralysis necessary, use peripheral nerve stimulator monitoring
Anticipate prolonged ventilation; early tracheostomy may be appropriate
Avoid ventilator-induced diaphragm dysfunction (optimize spontaneous breathing)

Disposition and Follow-Up

Admission Decisions

ICU admission indicated for:

Hemodynamic instability
High risk of clinical deterioration (massive PE, myasthenic crisis, severe metabolic acidosis)
Need for mechanical ventilation or close respiratory monitoring
Acute interventions required (thrombolysis, plasmapheresis)

Telemetry/step-down appropriate for:

Stable patients requiring continuous monitoring
PE patients on anticoagulation without high-risk features
Observation after acute interventions

Discharge considerations:

Low-risk PE (PESI class I-II) may be discharged on oral anticoagulation
Ensure adequate outpatient follow-up for chronic conditions (ILD, PH, HFpEF)
Arrange appropriate subspecialty consultation (pulmonology, cardiology, neurology)

Long-Term Management

PE survivors:

Duration of anticoagulation depends on risk factors (provoked vs. unprovoked)
Screen for post-PE syndrome and CTEPH (persistent dyspnea at 3-6 months warrants V/Q scan and echo)
Risk stratify for recurrence

Neuromuscular disorders:

Outpatient neurology follow-up
Respiratory function tests every 3-6 months
Home non-invasive ventilation if chronic respiratory failure
Advance care planning discussions

HFpEF:

Guideline-directed medical therapy optimization
Cardiac rehabilitation
Aggressive cardiovascular risk factor modification
Consider advanced therapies if refractory

Clinical Case Scenarios

Case 1: The Tachypneic Traveler

Presentation: A 34-year-old woman presents with sudden-onset dyspnea and right-sided pleuritic chest pain. She returned from Europe 5 days ago (8-hour flight). Vital signs: HR 110, RR 28, BP 118/72, SpO2 94% on room air. Physical exam reveals mild tachycardia but is otherwise unremarkable. CXR is clear.

Workup:

Wells score: 4.5 points (HR >100 = 1.5, alternative diagnosis less likely = 3)
D-dimer: 2,450 ng/mL (elevated)
CTPA: Multiple subsegmental pulmonary emboli in right lower lobe

Management:

Apixaban 10 mg BID × 7 days, then 5 mg BID
Assess bleeding risk
Low-risk PE (sPESI = 0) → discharged with close follow-up

Teaching point: Young, otherwise healthy patients with PE often have normal oxygen saturation. Don't let reassuring vitals delay workup when pre-test probability is high.

Case 2: The Diabetic with Deep Breathing

Presentation: A 28-year-old type 1 diabetic presents with progressive dyspnea over 24 hours. He's been vomiting and hasn't taken insulin for 2 days. RR 32, deep and labored. HR 118, BP 102/64, SpO2 99% on room air. CXR clear.

Workup:

ABG: pH 7.12, PaCO2 18, PaO2 108, HCO3 6, lactate 2.1
Glucose 542 mg/dL, beta-hydroxybutyrate 8.2 mmol/L, anion gap 28
Calculated expected PaCO2: (1.5 × 6) + 8 = 17 mmHg (appropriate compensation)

Diagnosis: Diabetic ketoacidosis with appropriate respiratory compensation (Kussmaul respirations)

Management:

IV fluids (1-2 L NS bolus, then 250-500 mL/hr)
Insulin infusion 0.1 units/kg/hr
Potassium repletion (anticipate hypokalemia with insulin)
Bicarbonate not indicated (pH >7.0)
Close monitoring for respiratory fatigue

Teaching point: The dyspnea will resolve as the acidosis corrects. Don't intubate unless absolutely necessary—matching the minute ventilation post-intubation is challenging.

Case 3: The Weak and Breathless

Presentation: A 58-year-old woman reports progressive weakness over 3 weeks, now with dyspnea. She notes difficulty chewing and double vision late in the day. CXR clear. On exam: bilateral ptosis, weak cough, paradoxical abdominal breathing.

Workup:

NIF: -18 cm H2O (severely reduced)
Vital capacity: 1.2 L (predicted 3.5 L)
Ice pack test: Ptosis improves
Anti-AChR antibodies: positive
CT chest: Thymic hyperplasia

Diagnosis: Myasthenia gravis with impending myasthenic crisis

Management:

ICU admission for close respiratory monitoring
IVIg 0.4 g/kg/day × 5 days
Pyridostigmine 60 mg PO Q6H
Intubation threshold: VC <15 mL/kg (patient at 17 mL/kg—borderline)
Trending NIF and VC Q4H

Teaching point: Don't wait for hypercapnia in neuromuscular weakness. The patient will exhaust before CO2 rises. Trend respiratory mechanics and intervene early.

Case 4: The Orthopneic Hypertensive

Presentation: A 72-year-old with long-standing hypertension presents with progressive dyspnea over several months, worse when lying flat. No chest pain. CXR shows clear lungs, borderline cardiomegaly. SpO2 93% on room air.

Workup:

BNP: 385 pg/mL (elevated but not markedly)
Echo: EF 62%, Grade 2 diastolic dysfunction, E/e' 16, LA volume index 42 mL/m²
H2FPEF score: 7 (high probability)

Diagnosis: Heart failure with preserved ejection fraction (HFpEF)

Management:

Furosemide 40 mg daily (symptom management)
Empagliflozin 10 mg daily
BP optimization (currently 156/88 → target <130/80)
Spironolactone 25 mg daily (if persistent symptoms)
Cardiac rehabilitation referral

Teaching point: HFpEF is underdiagnosed. Don't be falsely reassured by preserved EF on echo—look at diastolic parameters and calculate H2FPEF score.

Emerging Concepts and Future Directions

Biomarkers on the Horizon

MR-proANP (mid-regional pro-atrial natriuretic peptide):

May be superior to BNP for diagnosing HFpEF
Less affected by obesity
Useful for risk stratification

Troponin in PE:

Elevated high-sensitivity troponin indicates RV strain
Helps risk-stratify submassive PE
Guides decisions about advanced therapies

Soluble ST2 and galectin-3:

Emerging biomarkers for heart failure prognosis
May guide therapy intensity

Advanced Therapies

Percutaneous interventions for PE:

Catheter-directed thrombolysis
Mechanical thrombectomy devices
Lower bleeding risk than systemic thrombolysis
Expanding indications for submassive PE with RV dysfunction

Novel anticoagulants:

Factor XIa inhibitors in development (reduced bleeding risk)
Reversal agents improving (andexanet alfa for factor Xa inhibitors, idarucizumab for dabigatran)

Pulmonary hypertension treatments:

Sotatercept (activin signaling inhibitor) showing promise in PAH trials
Combination therapy increasingly standard

Gene therapy for neuromuscular disease:

Onasemnogene abeparvovec for spinal muscular atrophy
Developing therapies for Duchenne muscular dystrophy

Artificial Intelligence and Machine Learning

AI algorithms are being developed to:

Predict PE risk from clinical data
Identify subtle radiographic findings missed by humans
Predict which patients will require mechanical ventilation
Optimize ventilator settings

While promising, these technologies require rigorous validation before widespread adoption.

Key Take-Home Points

Dyspnea with a clear chest X-ray is common and demands systematic evaluation—don't anchor on the negative CXR.
Pulmonary embolism is the "can't miss" diagnosis—use validated decision tools (Wells, PERC) systematically, and don't let normal oxygen saturation provide false reassurance.
Metabolic acidosis produces dramatic dyspnea—always check ABG and calculate expected compensation. Prepare carefully before intubating these patients.
HFpEF is underdiagnosed—think diastolic heart failure in hypertensive, obese, elderly patients with exertional dyspnea. Calculate H2FPEF score and obtain echo.
Neuromuscular weakness requires early recognition—look for ptosis, weak cough, paradoxical breathing. Don't wait for hypercapnia to intervene.
Point-of-care ultrasound is invaluable—learn basic cardiac, lung, and vascular ultrasound. It rapidly narrows the differential at the bedside.
Calculate the A-a gradient—this simple calculation helps differentiate V/Q mismatch from hypoventilation and guides further workup.
Match pre-intubation minute ventilation—especially critical in metabolic acidosis and neuromuscular weakness. Inadequate post-intubation ventilation can be catastrophic.
Consider the clinical context—pregnancy, post-operative status, immunosuppression, and other factors expand the differential diagnosis.
Follow-up is essential—many of these conditions require chronic management. Ensure appropriate subspecialty referral and long-term monitoring.

Conclusion

The dyspneic patient with a clear chest radiograph represents one of critical care medicine's most challenging diagnostic dilemmas. Success requires abandoning algorithmic dependence on imaging findings and embracing a broader, systematic approach. By maintaining high clinical suspicion for pulmonary embolism, recognizing metabolic compensation patterns, identifying cardiac causes beyond systolic dysfunction, detecting neuromuscular weakness early, and considering less common pulmonary etiologies, clinicians can avoid diagnostic pitfalls and provide timely, life-saving interventions.

The integration of validated clinical decision rules, point-of-care ultrasound, targeted laboratory testing, and advanced imaging has revolutionized the evaluation of these complex patients. As our understanding evolves and new therapies emerge, intensivists must remain vigilant, curious, and humble—recognizing that the most important findings are sometimes what we don't see on the chest X-ray.

References

Banzett RB, Mulnier HE, Murphy K, et al. Breathlessness in humans activates insular cortex. Neuroreport. 2000;11(10):2117-2120.
Ryu JH, Olson EJ, Midthun DE, Swensen SJ. Diagnostic approach to the patient with diffuse lung disease. Mayo Clin Proc. 2002;77(11):1221-1227.
Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 Suppl):S495-501.
Worsley DF, Alavi A, Aronchick JM, Chen JT, Greenspan RH, Ravin CE. Chest radiographic findings in patients with acute pulmonary embolism: observations from the PIOPED Study. Radiology. 1993;189(1):133-136.
Stein PD, Beemath A, Matta F, et al. Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med. 2007;120(10):871-879.
Kline JA, Hernandez-Nino J, Jones AE, et al. Prospective study of the clinical features and outcomes of emergency department patients with delayed diagnosis of pulmonary embolism. Acad Emerg Med. 2007;14(7):592-598.
Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83(3):416-420.
Douma RA, Gibson NS, Gerdes VE, et al. Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thromb Haemost. 2009;101(1):197-200.
Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost. 2004;2(8):1247-1255.
Kline JA, Courtney DM, Kabrhel C, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008;6(5):772-780.
Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117-1124.
Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med. 2006;354(22):2317-2327.
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808.
Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311(23):2414-2421.
Lalau JD, Arnouts P, Sharif A, De Broe ME. Metformin and other antidiabetic agents in renal failure patients. Kidney Int. 2015;87(2):308-322.
Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194-202.
Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138(9):861-870.
Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461.
Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017-2023.
Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67(6):781-787.
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;(9):CD002063.
King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092.
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913.
Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340(6):409-417.
James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311-1315.
Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017;38(35):2671-2679.
Lichtenstein DA, Mezière GA. Relevance of lung ultrasound in the diagnosis of acute respiratory failure: the BLUE protocol. Chest. 2008;134(1):117-125.
Lichtenstein DA. FALLS-protocol: lung ultrasound in hemodynamic assessment of shock. Heart Lung Vessel. 2013;5(3):142-147.
Vital FMR, Saconato H, Ladeira MT, et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary edema. Cochrane Database Syst Rev. 2013;(5):

CD005351.

Roca O, Messika J, Caralt B, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. J Crit Care. 2016;35:200-205.
Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603.
Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):762-774.
Kitabatake A, Inoue M, Asao M, et al. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation. 1983;68(2):302-309.
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731.

Appendix A: Quick Reference Tables

Table 2: Differential Diagnosis by Tempo of Onset

Acute (<24 hours)	Subacute (days-weeks)	Chronic (months-years)
Pulmonary embolism	Myasthenia gravis	Interstitial lung disease
Metabolic acidosis	Guillain-Barré syndrome	Pulmonary hypertension
Acute MI	Subacute PE	HFpEF
Cardiac tamponade	Drug-induced pneumonitis	Chronic anemia
Pneumothorax (small)	Myocarditis	Deconditioning
Methemoglobinemia	Bacterial endocarditis	Obesity hypoventilation

Table 3: Physical Examination Findings and Associated Diagnoses

Physical Finding	Associated Diagnosis
Unilateral leg swelling, Homan's sign	DVT/PE
Loud P2, RV heave	Pulmonary hypertension, PE
Fruity breath odor, dry mucous membranes	DKA
Elevated JVP, peripheral edema	Right heart failure, PE, PH
Bibasilar fine crackles	ILD, early pulmonary edema
Opening snap, diastolic rumble	Mitral stenosis
Crescendo-decrescendo murmur, delayed carotid upstroke	Aortic stenosis
Ptosis, diplopia, fatigable weakness	Myasthenia gravis
Ascending weakness, areflexia	Guillain-Barré syndrome
Paradoxical breathing, weak cough	Diaphragm/neuromuscular weakness
Cyanosis despite oxygen, chocolate blood	Methemoglobinemia
Conjunctival pallor, tachycardia	Severe anemia

Table 4: Arterial Blood Gas Interpretation in Dyspnea

ABG Pattern	Diagnosis to Consider
Normal pH, PaCO2, PaO2, A-a gradient	Anxiety, hyperventilation, deconditioning
Respiratory alkalosis, normal A-a	Hyperventilation, anxiety, early PE, sepsis
Respiratory alkalosis, elevated A-a	PE, pneumonia, ILD, pulmonary edema
Metabolic acidosis, low PaCO2 (compensated)	DKA, lactic acidosis, renal failure, toxic ingestion
Metabolic acidosis, normal/high PaCO2	Respiratory muscle fatigue, impending arrest
Hypoxemia, normal A-a gradient	Hypoventilation (neuromuscular, drug overdose)
Hypoxemia, elevated A-a gradient	V/Q mismatch (PE, ILD, PH), shunt

Table 5: Bedside Tests and What They Tell You

Test	What It Measures	Clinical Utility
Single breath count	Vital capacity proxy	Screen for neuromuscular weakness (<15 abnormal)
NIF (Negative Inspiratory Force)	Inspiratory muscle strength	Intubation decision in weakness (<-30 cm H2O concerning)
Vital capacity	Lung volume, muscle strength	Trend in myasthenia/GBS (intubate if <15-20 mL/kg)
Orthostatic vital signs	Volume status, autonomic function	Assess for dehydration, GBS autonomic dysfunction
Ice pack test	Acetylcholine receptor function	Screen for myasthenia gravis (improved ptosis = positive)
Six-minute walk test	Exercise capacity, desaturation	Assess functional limitation, screen for ILD
ROX index	HFNC failure risk	Predict need for intubation (ROX <3.85 = high risk)

Appendix B: Drug-Induced Causes of Dyspnea with Clear CXR

Medications That Can Cause Dyspnea

Chemotherapeutic agents:

Bleomycin (pulmonary fibrosis)
Methotrexate (pneumonitis)
Cyclophosphamide (pneumonitis)
Checkpoint inhibitors (immune-mediated pneumonitis)
Gemcitabine (capillary leak syndrome)

Cardiac medications:

Amiodarone (pulmonary toxicity—may have clear CXR early)
Beta-blockers (exacerbate asthma/COPD, heart failure)
Aspirin (salicylate toxicity causing metabolic acidosis)

Antimicrobials:

Nitrofurantoin (acute or chronic pneumonitis)
Sulfonamides (hypersensitivity pneumonitis)

Illicit drugs:

Cocaine (cardiomyopathy, MI, pulmonary hemorrhage)
Methamphetamine (pulmonary hypertension, cardiomyopathy)
Opioids (respiratory depression)

Other:

Metformin (lactic acidosis)
Triptans (serotonin syndrome with agitation and tachypnea)
Chronic acetaminophen (pyroglutamic acidosis)

Pearl #19: Always obtain a complete medication history including over-the-counter drugs, supplements, and illicit substances. Drug-induced pulmonary toxicity is often a diagnosis of exclusion.

Appendix C: Scoring Systems and Calculators

Wells Score Calculator (Detailed)

Patient factors:

Clinical signs/symptoms of DVT (leg swelling, pain with palpation): 3.0 points
Alternative diagnosis less likely than PE: 3.0 points
Heart rate >100 bpm: 1.5 points
Immobilization ≥3 days OR surgery in previous 4 weeks: 1.5 points
Previous DVT or PE: 1.5 points
Hemoptysis: 1.0 point
Malignancy (treatment within 6 months or palliative): 1.0 point

Two-tier interpretation:

PE unlikely: ≤4 points (proceed to D-dimer)
PE likely: >4 points (proceed to imaging)

Three-tier interpretation (less commonly used):

Low probability: <2 points
Moderate probability: 2-6 points
High probability: >6 points

Geneva Score (Alternative to Wells)

Clinical factors:

Age >65 years: +1
Previous DVT or PE: +3
Surgery or fracture within 1 month: +2
Active malignancy: +2
Unilateral lower limb pain: +3
Hemoptysis: +2
Heart rate 75-94 bpm: +3
Heart rate ≥95 bpm: +5
Pain on lower limb deep palpation and unilateral edema: +4

Interpretation:

Low probability: 0-3 points
Intermediate probability: 4-10 points
High probability: ≥11 points

Simplified PESI Score (sPESI)

Assign 1 point for each:

Age >80 years
History of cancer
Chronic cardiopulmonary disease
Heart rate ≥110 bpm
Systolic BP <100 mmHg
Oxygen saturation <90%

Score 0 = very low risk (30-day mortality <1%) → consider outpatient management

Score ≥1 = higher risk → requires hospitalization

H2FPEF Score Calculator

Heavy (BMI >30 kg/m²): 2 points
Hypertensive (≥2 antihypertensive medications): 1 point
Atrial Fibrillation (paroxysmal or persistent): 3 points
Pulmonary hypertension (echo PASP >35 mmHg): 1 point
Elder (age >60 years): 1 point
Filling pressure (echo E/e' >9): 1 point

Interpretation:

0-1 points: Low probability of HFpEF (<25%)
2-5 points: Intermediate probability (50-75%)
6-9 points: High probability of HFpEF (>90%)

Appendix D: Ultrasound Protocols for Dyspnea

BLUE Protocol (Bedside Lung Ultrasound in Emergency)

Standard examination points:

Upper BLUE point: 2nd-3rd intercostal space, midclavicular line
Lower BLUE point: 4th-5th intercostal space, anterior axillary line
PLAPS point (posterolateral alveolar and/or pleural syndrome): Posterolateral chest wall, 5th intercostal space

Profiles and their diagnoses:

Profile	Findings	Diagnosis	Sensitivity/Specificity
A-profile	Bilateral A-lines, lung sliding	Normal lung or COPD/asthma	97%/95% for normal lung
B-profile	Bilateral B-lines (≥3 per view)	Cardiogenic pulmonary edema	97%/95% for pulmonary edema
A/B-profile	Unilateral B-lines	Pneumonia	93%/90% for pneumonia
C-profile	Anterior consolidation	Pneumonia	-
A-profile + DVT	A-lines + positive leg ultrasound	Pulmonary embolism	81%/99% for PE

FALLS Protocol (Fluid Administration Limited by Lung Sonography)

Goal: Prevent fluid overload during resuscitation

Method:

Scan bilateral anterior lung fields for B-lines before fluid administration
Administer 500 mL fluid bolus
Reassess for new/worsening B-lines
If B-lines appear → STOP fluids, consider inotropes/vasopressors
If no B-lines and patient still hypotensive → continue cautious fluid administration

Pearl #20: This protocol is particularly valuable in patients with unclear volume status (sepsis with diastolic dysfunction, PE with shock). It prevents iatrogenic pulmonary edema while allowing adequate resuscitation.

Diaphragm Ultrasound Technique

Probe placement:

High-frequency linear probe
Place at anterior axillary line, 8th-9th intercostal space
Visualize zone of apposition (diaphragm between liver/spleen and chest wall)

Measurements:

Diaphragm thickening fraction:
- Measure thickness at end-expiration and end-inspiration
- Thickening fraction = [(Thickness inspiration - Thickness expiration) / Thickness expiration] × 100
- Normal: >20%
- <20% suggests diaphragm weakness/dysfunction
Diaphragm excursion:
- M-mode cursor perpendicular to diaphragm
- Normal excursion: >1.5-2.0 cm
- <1.0 cm suggests dysfunction
Paradoxical movement:
- Diaphragm moves cranially (upward) during inspiration = paralysis

Hack #14: Diaphragm ultrasound is underutilized but invaluable. In difficult-to-wean patients, bilateral diaphragm dysfunction may be the culprit. A quick scan takes 5 minutes and can redirect management.

Appendix E: Common Pitfalls and How to Avoid Them

Pitfall #1: Anchoring on the Normal CXR

Mistake: Assuming a clear chest X-ray rules out significant pulmonary disease

Reality: Many life-threatening conditions present with normal radiographs (PE, early ILD, PH, diastolic heart failure)

Solution: Use the CXR as one data point, not the definitive answer. Let clinical presentation drive workup.

Pitfall #2: Over-relying on Oxygen Saturation

Mistake: Reassured by normal SpO2, missing diagnoses like PE, anemia, or early respiratory failure

Reality: Compensatory mechanisms maintain saturation until late in disease course

Solution: Focus on work of breathing, respiratory rate, and patient appearance. Trending is more valuable than single measurements.

Pitfall #3: Premature Closure with "Anxiety"

Mistake: Attributing dyspnea to anxiety without excluding organic causes

Reality: Anxious patients can have PE, MI, or other emergencies. Anxiety may be a symptom, not the diagnosis.

Solution: Complete workup first, diagnose anxiety only after exclusion of organic disease. Remember: "Dyspnea is never psychogenic until proven otherwise."

Pitfall #4: Missing Neuromuscular Weakness

Mistake: Not considering neuromuscular causes because "the lungs are clear"

Reality: Respiratory muscle weakness causes dyspnea despite normal lung parenchyma

Solution: Specifically ask about difficulty swallowing, double vision, progressive weakness. Examine for ptosis, weak cough, paradoxical breathing. Check NIF and VC.

Pitfall #5: Inadequate Post-Intubation Ventilation

Mistake: Using "standard" ventilator settings for patients with metabolic acidosis or high baseline minute ventilation

Reality: Sudden reduction in minute ventilation causes precipitous pH drop and cardiovascular collapse

Solution: Calculate pre-intubation minute ventilation and match it post-intubation. For metabolic acidosis patients, may need RR 25-30 and VT 6-8 mL/kg.

Pitfall #6: Ignoring Temporal Trends

Mistake: Making decisions based on single vital signs or lab values

Reality: Worsening trends are more predictive than absolute values

Solution: Graph respiratory rate, NIF/VC, lactate, pH over time. Deteriorating trends demand escalation even if absolute values aren't critical yet.

Pitfall #7: Using D-Dimer Inappropriately

Mistake: Checking D-dimer in high pre-test probability patients or critically ill patients

Reality: Elevated D-dimer in ICU patients is nearly universal and unhelpful. Negative D-dimer in high-risk patients doesn't rule out PE (sensitivity decreases with high pre-test probability).

Solution: Use D-dimer only in low-to-moderate pre-test probability patients. In high-risk or ICU patients, proceed directly to imaging.

Pitfall #8: Assuming "Diastolic Dysfunction" Is Benign

Mistake: Dismissing echo report of "grade 2 diastolic dysfunction" as unimportant

Reality: Significant diastolic dysfunction causes symptomatic heart failure and pulmonary edema

Solution: Calculate H2FPEF score, check BNP, and treat as HFpEF if clinical picture fits. Don't be fooled by preserved EF.

Appendix F: Procedure Tips for the Dyspneic Patient

Safe Intubation of the Dyspneic Patient

Pre-intubation optimization:

Preoxygenation: Use high-flow nasal cannula at 60 L/min during apnea (apneic oxygenation extends safe apnea time)[32]
Positioning: Ramped position (head-elevated laryngoscopy position) improves First Pass Success
Hemodynamic preparation:
- For PE patients: Have vasopressors ready (intubation drops venous return)
- For metabolic acidosis: Consider bicarbonate bolus pre-intubation
- Fluid bolus for most patients (500-1000 mL) to counteract positive pressure effects

Induction agent selection:

Ketamine 1-2 mg/kg: Maintains sympathetic tone, good for hemodynamically unstable patients
Etomidate 0.3 mg/kg: Hemodynamically neutral, but avoid in sepsis if possible
Propofol 1-2 mg/kg: Causes hypotension, use cautiously in unstable patients

Avoid succinylcholine in:

Hyperkalemia
Chronic neuromuscular disease
Burns >24 hours old
Crush injuries

Post-intubation ventilator settings:

Volume control initially for guaranteed minute ventilation
Tidal volume: 6-8 mL/kg ideal body weight
Respiratory rate: Match pre-intubation minute ventilation
- For metabolic acidosis: Often requires RR 25-35
- For normal patients: Start RR 12-16
PEEP: 5-8 cm H2O (lower in PE to avoid RV afterload)
FiO2: 100% initially, wean rapidly as tolerated

Hack #15: Calculate target minute ventilation before intubation. Formula: Current MV = RR × Estimated VT (rough estimate: 7-8 mL/kg for dyspneic patients). Set ventilator to deliver this MV. Check ABG 20-30 minutes post-intubation and adjust.

Procedural Sedation in Dyspneic Patients

High-risk scenario: Sedation can precipitate respiratory failure

Risk assessment:

ASA class ≥3
Severe systemic disease
Respiratory rate >25
Oxygen saturation <90%
Inability to lie flat

Safer approaches:

Ketamine: Maintains respiratory drive, good for painful procedures
Dexmedetomidine: Minimal respiratory depression (but slow onset)
Avoid: Propofol, benzodiazepines, opioids (all cause respiratory depression)

Monitoring:

Continuous pulse oximetry
Capnography (detects hypoventilation before desaturation)
Blood pressure monitoring
Have reversal agents ready (naloxone, flumazenil)
Low threshold for intubation

Appendix G: Communication Pearls

Discussing Prognosis with Patients and Families

For PE:

"Pulmonary embolism is a serious condition, but with treatment most patients recover well. The blood thinner prevents new clots and allows your body to dissolve the existing ones over time."
If massive PE: "This is a life-threatening emergency. We're considering clot-busting medication, which has risks but may save their life."

For neuromuscular weakness:

"The weakness is affecting the breathing muscles. We may need to temporarily support breathing with a machine while we treat the underlying condition."
"Recovery from Guillain-Barré can take weeks to months. Most people eventually regain strength, but it's a slow process requiring patience and rehabilitation."

For HFpEF:

"The heart's pumping function is normal, but the heart muscle is stiff and doesn't relax well. This causes fluid to back up into the lungs, making breathing difficult."
"This is a chronic condition requiring long-term management with medications, blood pressure control, and lifestyle changes."

For ILD:

"There are many types of lung scarring. We need specialized testing to determine which type you have, because treatment varies."
If IPF diagnosed: "This is a progressive condition without a cure, but medications can slow progression. Lung transplantation is an option for some patients."

Informed Consent Discussions

For intubation:

"Your breathing is getting more difficult. We may need to place a breathing tube and use a ventilator to support you while we treat the underlying problem."
Risks: "Common risks include sore throat, hoarseness, and dental injury. Rare but serious risks include damage to the vocal cords, pneumonia, and difficulty removing the tube later."

For thrombolysis:

"The clot-busting medication can save your life, but it carries about a 2-3% risk of serious bleeding, including brain hemorrhage."
"Given the severity of your condition, we believe the benefits outweigh the risks, but this is your decision."

Pearl #21: Use the "teach-back" method: After explaining, ask the patient/family to explain back to you what they understood. This ensures comprehension and identifies gaps.

Final Thoughts: The Art and Science of Critical Care

The evaluation of dyspnea with a clear chest radiograph epitomizes the dual nature of critical care medicine—it requires both scientific rigor and clinical artistry. The scientific approach provides validated decision rules, diagnostic algorithms, and evidence-based management strategies. The clinical art involves recognizing subtle patterns, integrating disparate data points, and maintaining diagnostic humility.

Several themes recur throughout this review:

1. Clinical context matters: The 30-year-old post-flight patient with unilateral leg swelling and the 70-year-old with hypertension and exertional dyspnea require entirely different approaches, despite both having clear chest X-rays.

2. Trends trump snapshots: Serial measurements of vital signs, respiratory mechanics, and laboratory values guide decision-making more reliably than isolated values.

3. Don't wait too long: Early intervention in myasthenic crisis, metabolic acidosis, or massive PE improves outcomes. By the time hypercapnia develops in neuromuscular weakness, the patient is exhausted.

4. Team-based care: These complex patients benefit from multidisciplinary input—cardiology, pulmonology, neurology, and others bring specialized expertise.

5. Bedside assessment remains paramount: Despite technological advances, physical examination, patient interaction, and clinical gestalt remain irreplaceable.

As critical care evolves, new diagnostic tools and therapies will emerge. Point-of-care ultrasound, artificial intelligence algorithms, and novel biomarkers will enhance our capabilities. However, the fundamental skill of systematic evaluation combined with clinical reasoning will remain central to excellent critical care practice.

The dyspneic patient with a clear chest X-ray reminds us that medicine remains both science and art, that the most important findings may be what we don't see on imaging, and that careful, thoughtful evaluation saves lives.

Acknowledgments

The author thanks the critical care community for continued dedication to evidence-based practice and the patients who teach us daily. Special recognition to the intensivists, respiratory therapists, nurses, and trainees whose collaborative care exemplifies modern critical care medicine.

Disclosure Statement

The author has no relevant financial conflicts of interest to disclose.